

GenCore version 4.5
Copyright (c) 1993 - 2000 Comugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 18, 2000, 19:10:45 ; Search time 39.33 seconds
(without alignments)
59.490 Million cell updates/sec

Title: PCR-US97-18348-1

Perfect score: 18
Sequence: 1 CAGCGTGGCGCATCCTTC 18

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 230463 seqs, 64992525 residues

Total number of hits satisfying chosen parameters: 328916

Minimum DB seq length: 0
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Listing first 45 summaries

Database : Issued_Patents_MA:*
1: /cgn2_6/ptodata/2/lna/5A.COMB.seq:*
2: /cgn2_6/ptodata/2/lna/5B.COMB.seq:*
3: /cgn2_6/ptodata/2/lna/5C.COMB.seq:*
4: /cgn2_6/ptodata/2/lna/5D.COMB.seq:*
5: /cgn2_6/ptodata/2/lna/5.COMB.seq:*
6: /cgn2_6/ptodata/2/lna/5.PCTUS.COMB.seq:*
7: /cgn2_6/ptodata/2/lna/backfiles1.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	18	100.0	20	2	US-08-217-082A-1
2	18	100.0	20	2	US-08-217-082A-7
3	18	100.0	20	3	US-08-465-485A-1
4	18	100.0	20	3	US-08-465-485A-7
5	18	100.0	20	3	US-09-080-285-1
6	18	100.0	20	5	US-09-080-285-7
7	18	100.0	35	2	US-08-217-082A-2
8	18	100.0	35	3	US-08-465-485A-2
9	18	100.0	35	5	US-09-080-285-2
10	16	88.9	17	2	US-08-217-082A-10
11	16	88.9	17	2	US-08-217-082A-11
12	13	72.2	17	2	US-08-217-082A-9
13	13	72.2	17	2	US-08-217-082A-12
14	13	72.2	18	3	US-08-217-082A-17
15	13	72.2	18	3	US-08-465-485A-17
16	13	72.2	18	3	US-08-465-485A-24
17	13	72.2	18	3	US-09-080-285-17
18	13	72.2	18	5	US-09-080-285-24
19	13	72.2	27	1	US-08-410-804-13
20	13	72.2	27	2	US-08-607-269-8
21	13	72.2	27	2	US-08-259-514-13
22	13	72.2	27	3	US-08-858-311-13
23	13	72.2	27	6	PCT-US95-04600-8
24	12.2	67.8	30	6	PCT-US94-10257A-37
25	11.8	65.6	31	4	US-08-837-190C-1
26	11.8	65.6	31	4	US-08-837-190C-11
27	11.8	65.6	31	2	US-08-647-584-44

c 28	11.8	65.6	45	1	US-07-795-859B-36	Sequence 36, Appl
c 29	11.8	65.6	45	1	US-08-457-616-36	Sequence 36, Appl
30	11.8	65.6	48	2	US-08-741-881-41	Sequence 41, Appl
31	11.8	65.6	48	2	US-08-739-158-41	Sequence 41, Appl
32	11.8	65.6	48	3	US-08-739-167-41	Sequence 41, Appl
33	11.8	65.6	48	5	US-08-404-796-41	Sequence 41, Appl
34	11.8	65.6	48	5	US-08-931-869-41	Sequence 41, Appl
35	11.4	63.3	25	6	PCT-US93-01857-3	Sequence 3, Appl
36	11.4	63.3	33	5	US-08-650-726-1	Sequence 1, Appl
c 37	11.2	62.2	47	6	PCT-US95-13552-16	Sequence 16, Appl
c 38	11.2	62.2	47	6	PCT-US95-13552-18	Sequence 16, Appl
c 39	11	61.1	19	7	5276019-8	Patent No. 5276019
c 40	11	61.1	31	2	US-08-726-136-19	Sequence 19, Appl
41	10.8	60.0	17	1	US-08-233-030-15	Sequence 15, Appl
c 42	10.8	60.0	21	5	US-08-804-439A-56	Sequence 56, Appl
c 43	10.8	60.0	21	5	US-08-720-229-56	Sequence 56, Appl
c 44	10.8	60.0	35	1	US-07-783-861C-19	Sequence 19, Appl
45	10.8	60.0	35	1	US-07-783-861C-22	Sequence 22, Appl

ALIGNMENTS

RESULT 1
US-08-217-082A-1
; Sequence 1, Application US/08217082A
; Patent No. 5734033
; GENERAL INFORMATION:
; APPLICANT: Reed, John
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES FOR INHIBITING THE
; TITLE OF INVENTION: GROWTH OF CELLS EXPRESSING THE HUMAN BCL-2 GENE
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
; STREET: 224 Airport Parkway
; CITY: San Jose
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 95110
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/217,082A
; FILING DATE: 24-MAR-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/840,716
; FILING DATE: 21-FEB-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/288,692
; FILING DATE: 22-DEC-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Fortney, Andrew D.
; REGISTRATION NUMBER: 34,600
; REFERENCE/DOCKET NUMBER: 3335-067-55 FMC
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (408) 436-2070
; TELEFAX: (408) 436-2075
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: Synthetic DNA
; ANTI-SENSE: YES
; US-08-217-082A-1

Query Match 100.0%; Score 18; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.24;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CAGCGTGGCCATCCTTC 18
|||||
Db 1 CAGCGTGGCCATCCTTC 18

RESULT 2

US-08-217-082A-7/c
; Sequence 7, Application US/08217082A
; Patent No. 573403
; GENERAL INFORMATION:
; APPLICANT: Reed, John
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES FOR INHIBITING THE
; GROWTH OF CELLS EXPRESSING THE HUMAN BCL-2 GENE
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: P.C.
; STREET: 224 Airport Parkway
; CITY: San Jose
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 95110
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/217,082A
; FILING DATE: 24-MAR-1994
; CLASSIFICATION: 435
; PRIORITY INFORMATION:
; APPLICATION NUMBER: US 07/840,716
; FILING DATE: 21-FEB-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/288,692
; FILING DATE: 22-DEC-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Fortney, Andrew D.
; REGISTRATION NUMBER: 34,600
; REFERENCE/DOCKET NUMBER: 3335-067-55 FWC
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (408) 436-2070
; TELEFAX: (408) 436-2075
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: Synthetic DNA
; ANTI-SENSE: NO
; US-08-217-082A-7

Query Match 100.0%; Score 18; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.24;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CAGCGTGGCCATCCTTC 18
|||||
Db 20 CAGCGTGGCCATCCTTC 3

RESULT 3

US-08-465-485A-1
; Sequence 1, Application US/08465485A

; Patent No. 5831066
; GENERAL INFORMATION:
; APPLICANT: Reed, John
; TITLE OF INVENTION: Regulation of bcl-2 Gene Expression
; NUMBER OF SEQUENCES: 28
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: P.C.
; STREET: 1755 S. Jefferson Davis Hwy., Suite 400
; CITY: Arlington
; STATE: Virginia
; COUNTRY: U.S.A.
; ZIP: 22202

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/465,485A
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 514
; PRIORITY INFORMATION:
; APPLICATION NUMBER: US 08/124,256
; FILING DATE: 20-SEP-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/840,716
; FILING DATE: 21-FEB-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/288,692
; FILING DATE: 22-DEC-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Fortney, Andrew D.
; REGISTRATION NUMBER: 34,600
; REFERENCE/DOCKET NUMBER: 3335-070-55 CONT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (408) 436-2070
; TELEFAX: (408) 436-2075
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; ANTI-SENSE: YES
; US-08-465-485A-1

Query Match 100.0%; Score 18; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.24;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CAGCGTGGCCATCCTTC 18
|||||
Db 1 CAGCGTGGCCATCCTTC 18

RESULT 4

US-08-465-485A-7/c
; Sequence 7, Application US/08465485A
; Patent No. 5831066
; GENERAL INFORMATION:
; APPLICANT: Reed, John
; TITLE OF INVENTION: Regulation of bcl-2 Gene Expression
; NUMBER OF SEQUENCES: 28
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: P.C.
; STREET: 1755 S. Jefferson Davis Hwy., Suite 400
; CITY: Arlington
; STATE: Virginia
; COUNTRY: U.S.A.

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/465,485A
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 514
; PRIORITY INFORMATION:
; APPLICATION NUMBER: US 08/124,256
; FILING DATE: 20-SEP-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/840,716
; FILING DATE: 21-FEB-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/288,692
; FILING DATE: 22-DEC-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Fortney, Andrew D.
; REGISTRATION NUMBER: 34,600
; REFERENCE/DOCKET NUMBER: 3335-070-55 CONT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (408) 436-2070
; TELEFAX: (408) 436-2075
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; ANTI-SENSE: YES
; US-08-465-485A-1

ZIP: 22202
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/465,485A
FILING DATE: 05-JUN-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/124,256
FILING DATE: 20-SEP-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/840,716
FILING DATE: 21-FEB-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/288,692
FILING DATE: 22-DEC-1988
ATTORNEY/AGENT INFORMATION:
NAME: Fortney, Andrew D.
REGISTRATION NUMBER: 34,600
REFERENCE/DOCKET NUMBER: 3335-070-55 CONT
TELECOMMUNICATION INFORMATION:
TELEPHONE: (408) 436-2070
TELEFAX: (408) 436-2075
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
ANTI-SENSE: NO
US-08-465-485A-7

Query Match 100.0%; Score 18; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.24;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CACCGTGGCCGATCCTTC 18
Db 20 CACGTGGCCGATCCTTC 3

RESULT 5
US-09-080-285-1
Sequence 1, Application US/09080285
Patent No. 6040181
GENERAL INFORMATION:
APPLICANT: Reed, John
TITLE OF INVENTION: Regulation of bcl-2 Gene Expression
NUMBER OF SEQUENCES: 29
CORRESPONDENCE ADDRESS:
ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
ADDRESSER: P.C.
STREET: 1755 S. Jefferson Davis Hwy., Suite 400
CITY: Arlington
STATE: Virginia
COUNTRY: U.S.A.
ZIP: 22202
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/080,285
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/465,485

FILING DATE: 05-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/124,256
FILING DATE: 20-SEP-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/840,716
FILING DATE: 21-FEB-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/288,692
FILING DATE: 22-DEC-1988
ATTORNEY/AGENT INFORMATION:
NAME: Fortney, Andrew D.
REGISTRATION NUMBER: 34,600
REFERENCE/DOCKET NUMBER: 3335-070-55 CONT
TELECOMMUNICATION INFORMATION:
TELEPHONE: (408) 436-2070
TELEFAX: (408) 436-2075
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
ANTI-SENSE: YES
US-09-080-285-1

Query Match 100.0%; Score 18; DB 5; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.24;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CACGTGGCCGATCCTTC 18
Db 1 CACGTGGCCGATCCTTC 18

RESULT 6
US-09-080-285-7/c
Sequence 7, Application US/09080285
Patent No. 6040181
GENERAL INFORMATION:
APPLICANT: Reed, John
TITLE OF INVENTION: Regulation of bcl-2 Gene Expression
NUMBER OF SEQUENCES: 29
CORRESPONDENCE ADDRESS:
ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
ADDRESSER: P.C.
STREET: 1755 S. Jefferson Davis Hwy., Suite 400
CITY: Arlington
STATE: Virginia
COUNTRY: U.S.A.
ZIP: 22202
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/080,285
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/465,485
FILING DATE: 05-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/124,256
FILING DATE: 20-SEP-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/840,716
FILING DATE: 21-FEB-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/288,692

FILING DATE: 22-DEC-1988
ATTORNEY/AGENT INFORMATION:
NAME: Fortney, Andrew D.
REGISTRATION NUMBER: 34,600
REFERENCE/DOCKET NUMBER: 3335-070-55 CONT
TELECOMMUNICATION INFORMATION:
TELEPHONE: (408) 436-2070
TELEFAX: (408) 436-2075
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
ANTI-SENSE: NO
US-09-080-285-7

Query Match 100.0%; Score 18; DB 5; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.24;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGCGTGGCCATCCTTC 18
|||||

Db 20 CAGCGTGGCCATCCTTC 3

RESULT 7
US-08-217-082A-2/C
Sequence 2, Application US/08217082A
Patent No. 5734033
GENERAL INFORMATION:
APPLICANT: Reed, John
TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES FOR INHIBITING THE
TITLE OF INVENTION: GROWTH OF CELLS EXPRESSING THE HUMAN BCL-2 GENE
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESS:
ADDRESSEE: OBILON, SPIVAK, MCCLELLAND, MATER & NEUSTADT,
ADDRESSEE: P.C.
STREET: 224 Airport Parkway
CITY: San Jose
STATE: California
COUNTRY: U.S.A.
ZIP: 95110
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/217,082A
FILING DATE: 24-MAR-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/840,716
FILING DATE: 21-FEB-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/288,692
FILING DATE: 22-DEC-1988
ATTORNEY/AGENT INFORMATION:
NAME: Fortney, Andrew D.
REGISTRATION NUMBER: 34,600
REFERENCE/DOCKET NUMBER: 3335-067-55 FMC
TELECOMMUNICATION INFORMATION:
TELEPHONE: (408) 436-2070
TELEFAX: (408) 436-2075
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 35 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)
ANTI-SENSE: NO
US-08-217-082A-2

Query Match 100.0%; Score 18; DB 2; Length 35;
Best Local Similarity 100.0%; Pred. No. 0.26;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGCGTGGCCATCCTTC 18
|||||

Db 30 CAGCGTGGCCATCCTTC 13

RESULT 8
US-08-465-485A-2/C
Sequence 2, Application US/08465485A
Patent No. 5831066
GENERAL INFORMATION:
APPLICANT: Reed, John
TITLE OF INVENTION: Regulation of bcl-2 Gene Expression
NUMBER OF SEQUENCES: 29
CORRESPONDENCE ADDRESS:
ADDRESSEE: OBILON, SPIVAK, MCCLELLAND, MATER & NEUSTADT,
ADDRESSEE: P.C.
STREET: 1755 S. Jefferson Davis Hwy., Suite 400
CITY: Arlington
STATE: Virginia
COUNTRY: U.S.A.
ZIP: 22202
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/465,485A
FILING DATE: 05-JUN-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/124,256
FILING DATE: 20-SEP-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/840,716
FILING DATE: 21-FEB-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/288,692
FILING DATE: 22-DEC-1988
ATTORNEY/AGENT INFORMATION:
NAME: Fortney, Andrew D.
REGISTRATION NUMBER: 34,600
REFERENCE/DOCKET NUMBER: 3335-070-55 CONT
TELECOMMUNICATION INFORMATION:
TELEPHONE: (408) 436-2070
TELEFAX: (408) 436-2075
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 35 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
ANTI-SENSE: NO
US-08-465-485A-2

Query Match 100.0%; Score 18; DB 3; Length 35;
Best Local Similarity 100.0%; Pred. No. 0.26;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGCGTGGCCATCCTTC 18
|||||

Db 30 CAGCGTGGCCATCCTTC 13

RESULT 9
US-09-080-285-2/c
; Sequence 2, Application US/09080285
; Patent No. 6040181
; GENERAL INFORMATION:
; APPLICANT: Reed, John
; TITLE OF INVENTION: Regulation of bcl-2 Gene Expression
; NUMBER OF SEQUENCES: 29
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
; STREET: 1755 S. Jefferson Davis Hwy., Suite 400
; CITY: Arlington
; STATE: Virginia
; COUNTRY: U.S.A.
; ZIP: 22202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/080,285
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/465,485
; FILING DATE: 05-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/124,256
; FILING DATE: 20-SEP-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/840,716
; FILING DATE: 21-FEB-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/288,692
; FILING DATE: 22-DEC-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Fortney, Andrew D.
; REGISTRATION NUMBER: 34,600
; REFERENCE/DOCKET NUMBER: 3335-070-55 CONT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (408) 436-2070
; TELEFAX: (408) 436-2075
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; ANTI-SENSE: NO
US-09-080-285-2

Query Match 100.0%; Score 18; DB 5; Length 35;
Best Local Similarity 100.0%; Pred. No. 0.26;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CACGTCGCCATCTTC 18
Db 30 CACGTCGCCATCTTC 13

RESULT 10
US-08-217-082A-10
; Sequence 10, Application US/08217082A
; Patent No. 5734033
; GENERAL INFORMATION:
; APPLICANT: Reed, John
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES FOR INHIBITING THE

; TITLE OF INVENTION: GROWTH OF CELLS EXPRESSING THE HUMAN BCL-2 GENE
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
; STREET: 224 Airport Parkway
; CITY: San Jose
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 95110
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/217,082A
; FILING DATE: 24-MAR-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/840,716
; FILING DATE: 21-FEB-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/288,692
; FILING DATE: 22-DEC-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Fortney, Andrew D.
; REGISTRATION NUMBER: 34,600
; REFERENCE/DOCKET NUMBER: 3335-067-55 FWC
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (408) 436-2070
; TELEFAX: (408) 436-2075
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: Synthetic DNA
; ANTI-SENSE: YES
US-08-217-082A-10

Query Match 88.9%; Score 16; DB 2; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.8;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CACGTCGCCATCTT 16
Db 2 CACGTCGCCATCTT 17

RESULT 11
US-08-217-082A-11
; Sequence 11, Application US/08217082A
; Patent No. 5734033
; GENERAL INFORMATION:
; APPLICANT: Reed, John
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES FOR INHIBITING THE
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
; STREET: 224 Airport Parkway
; CITY: San Jose
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 95110
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/217,082A
FILING DATE: 24-MAR-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/840,716
FILING DATE: 21-FEB-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/288,692
FILING DATE: 22-DEC-1988
ATTORNEY/AGENT INFORMATION:
NAME: Fortney, Andrew D.
REGISTRATION NUMBER: 34,600
REFERENCE/DOCKET NUMBER: 3335-067-55 FWC
TELECOMMUNICATION INFORMATION:
TELEPHONE: (408) 436-2070
FAX: (408) 436-2075
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: Synthetic DNA
ANTI-SENSE: YES
US-08-217-082A-11

Query Match 88.9%; Score 16; DB 2; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.8;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 GCGTGGCCATCCTTC 18
|||||
DB 1 GCGTGGCCATCCTTC 16

RESULT 12
US-08-217-082A-9
Sequence 9, Application US/08217082A
Patent No. 5734033
GENERAL INFORMATION:
APPLICANT: Reed, John
TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES FOR INHIBITING THE
GROWTH OF CELLS EXPRESSING THE HUMAN BCL-2 GENE
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESS:
ADDRESSEE: P.C.
STREET: 224 Airport Parkway
CITY: San Jose
STATE: California
COUNTRY: U.S.A.
ZIP: 95110
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/217,082A
FILING DATE: 24-MAR-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/840,716
FILING DATE: 21-FEB-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/288,692
FILING DATE: 22-DEC-1988
ATTORNEY/AGENT INFORMATION:

NAME: Fortney, Andrew D.
REGISTRATION NUMBER: 34,600
REFERENCE/DOCKET NUMBER: 3335-067-55 FWC
TELECOMMUNICATION INFORMATION:
TELEPHONE: (408) 436-2070
FAX: (408) 436-2075
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: Synthetic DNA
ANTI-SENSE: YES
US-08-217-082A-9

Query Match 72.2%; Score 13; DB 2; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGCGTGGCCAT 13
|||||
DB 5 CAGCGTGGCCAT 17

RESULT 13
US-08-217-082A-12
Sequence 12, Application US/08217082A
Patent No. 5734033
GENERAL INFORMATION:
APPLICANT: Reed, John
TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES FOR INHIBITING THE
GROWTH OF CELLS EXPRESSING THE HUMAN BCL-2 GENE
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESS:
ADDRESSEE: P.C.
STREET: 224 Airport Parkway
CITY: San Jose
STATE: California
COUNTRY: U.S.A.
ZIP: 95110
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/217,082A
FILING DATE: 24-MAR-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/840,716
FILING DATE: 21-FEB-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/288,692
FILING DATE: 22-DEC-1988
ATTORNEY/AGENT INFORMATION:
NAME: Fortney, Andrew D.
REGISTRATION NUMBER: 34,600
REFERENCE/DOCKET NUMBER: 3335-067-55 FWC
TELECOMMUNICATION INFORMATION:
TELEPHONE: (408) 436-2070
FAX: (408) 436-2075
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid

DESCRIPTION: Synthetic DNA
ANTI-SENSE: YES
US-08-217-082A-12

Query Match 72.2%; Score 13; DB 2; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 6 TGGCCATCCTC 18
|||||
DB 1 TGGCCATCCTC 13

RESULT 14
US-08-217-082A-17
Sequence 17, Application US/08217082A
Patent No. 5734033
GENERAL INFORMATION:
APPLICANT: Reed, John
TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES FOR INHIBITING THE
TITLE OF INVENTION: GROWTH OF CELLS EXPRESSING THE HUMAN BCL-2 GENE
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESS:
ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
ADDRESS: P.C.
STREET: 224 Airport Parkway
CITY: San Jose
STATE: California
COUNTRY: U.S.A.
ZIP: 95110
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/217,082A
FILING DATE: 24-MAR-1994
CLASSIFICATION: 435
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US 07/840,716
FILING DATE: 21-FEB-1992
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US 07/288,692
FILING DATE: 22-DEC-1988
ATTORNEY/AGENT INFORMATION:
NAME: Fortney, Andrew D.
REGISTRATION NUMBER: 34,600
REFERENCE/DOCKET NUMBER: 3335-067-55 FWC
TELECOMMUNICATION INFORMATION:
TELEPHONE: (408) 436-2070
TELEFAX: (408) 436-2075
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: Synthetic DNA
US-08-217-082A-17

Query Match 72.2%; Score 13; DB 2; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CACGTCGCCCAT 13
|||||
DB 6 CACGTCGCCCAT 18

RESULT 15
US-08-465-485A-17
Sequence 17, Application US/08465485A
Patent No. 5831066
GENERAL INFORMATION:
APPLICANT: Reed, John
TITLE OF INVENTION: Regulation of bcl-2 Gene Expression
NUMBER OF SEQUENCES: 29
CORRESPONDENCE ADDRESS:
ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
ADDRESS: P.C.
STREET: 1755 S. Jefferson Davis Hwy., Suite 400
CITY: Arlington
STATE: Virginia
COUNTRY: U.S.A.
ZIP: 22202

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/465,485A
FILING DATE: 05-JUN-1995
CLASSIFICATION: 514
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US 08/124,256
FILING DATE: 20-SEP-1993
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US 07/840,716
FILING DATE: 21-FEB-1992
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US 07/288,692
FILING DATE: 22-DEC-1988
ATTORNEY/AGENT INFORMATION:
NAME: Fortney, Andrew D.
REGISTRATION NUMBER: 34,600
REFERENCE/DOCKET NUMBER: 3335-070-55 CONT
TELECOMMUNICATION INFORMATION:
TELEPHONE: (408) 436-2070
TELEFAX: (408) 436-2075
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-465-485A-17

Query Match 72.2%; Score 13; DB 3; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CACGTCGCCCAT 13
|||||
DB 6 CACGTCGCCCAT 18

Search completed: June 18, 2000, 20:47:49
Job time: 5824 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 18, 2000, 20:30:39 ; Search time 288.74 Seconds

(without alignments)
-248.529 Million cell updates/sec

Title: PCT-US97-18348-1
Perfect score: 18
Sequence: 1 CAGCGTGGCCATCCTTC 18

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 5297623 seqs, -199338314 residues

Total number of hits satisfying chosen parameters: 915250

Minimum DB seq length: 0
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Listing first 45 summaries

Database :

Pending_Patents_NA:*
1: /cgn2_6/ptodata/2/pna/PCTUS_COMB.seq:*
2: /cgn2_6/ptodata/2/pna/US06_COMB.seq:*
3: /cgn2_6/ptodata/2/pna/US07_COMB.seq:*
4: /cgn2_6/ptodata/2/pna/US08_COMB.seq:*
5: /cgn2_6/ptodata/2/pna/US081A_COMB.seq:*
6: /cgn2_6/ptodata/2/pna/US081B_COMB.seq:*
7: /cgn2_6/ptodata/2/pna/US081C_COMB.seq:*
8: /cgn2_6/ptodata/2/pna/US081D_COMB.seq:*
9: /cgn2_6/ptodata/2/pna/US082A_COMB.seq:*
10: /cgn2_6/ptodata/2/pna/US082B_COMB.seq:*
11: /cgn2_6/ptodata/2/pna/US082C_COMB.seq:*
12: /cgn2_6/ptodata/2/pna/US083A_COMB.seq:*
13: /cgn2_6/ptodata/2/pna/US083B_COMB.seq:*
14: /cgn2_6/ptodata/2/pna/US084A_COMB.seq:*
15: /cgn2_6/ptodata/2/pna/US084B_COMB.seq:*
16: /cgn2_6/ptodata/2/pna/US084C_COMB.seq:*
17: /cgn2_6/ptodata/2/pna/US085_COMB.seq:*
18: /cgn2_6/ptodata/2/pna/US086_COMB.seq:*
19: /cgn2_6/ptodata/2/pna/US087A_COMB.seq:*
20: /cgn2_6/ptodata/2/pna/US087B_COMB.seq:*
21: /cgn2_6/ptodata/2/pna/US087C_COMB.seq:*
22: /cgn2_6/ptodata/2/pna/US088A_COMB.seq:*
23: /cgn2_6/ptodata/2/pna/US088B_COMB.seq:*
24: /cgn2_6/ptodata/2/pna/US088C_COMB.seq:*
25: /cgn2_6/ptodata/2/pna/US088D_COMB.seq:*
26: /cgn2_6/ptodata/2/pna/US089A_COMB.seq:*
27: /cgn2_6/ptodata/2/pna/US089B_COMB.seq:*
28: /cgn2_6/ptodata/2/pna/US089C_COMB.seq:*
29: /cgn2_6/ptodata/2/pna/US089D_COMB.seq:*
30: /cgn2_6/ptodata/2/pna/US089E_COMB.seq:*
31: /cgn2_6/ptodata/2/pna/US089F_COMB.seq:*
32: /cgn2_6/ptodata/2/pna/US089G_COMB.seq:*
33: /cgn2_6/ptodata/2/pna/US089H_COMB.seq:*
34: /cgn2_6/ptodata/2/pna/US089I_COMB.seq:*
35: /cgn2_6/ptodata/2/pna/US090A_COMB.seq:*
36: /cgn2_6/ptodata/2/pna/US090B_COMB.seq:*
37: /cgn2_6/ptodata/2/pna/US090C_COMB.seq:*
38: /cgn2_6/ptodata/2/pna/US090D_COMB.seq:*
39: /cgn2_6/ptodata/2/pna/US090E_COMB.seq:*
40: /cgn2_6/ptodata/2/pna/US091A_COMB.seq:*
41: /cgn2_6/ptodata/2/pna/US091B_COMB.seq:*
42: /cgn2_6/ptodata/2/pna/US091C_COMB.seq:*
43: /cgn2_6/ptodata/2/pna/US092A_COMB.seq:*
44: /cgn2_6/ptodata/2/pna/US092B_COMB.seq:*

45: /cgn2_6/ptodata/2/pna/US092C_COMB.seq:*
46: /cgn2_6/ptodata/2/pna/US092D_COMB.seq:*
47: /cgn2_6/ptodata/2/pna/US092E_COMB.seq:*
48: /cgn2_6/ptodata/2/pna/US093A_COMB.seq:*
49: /cgn2_6/ptodata/2/pna/US093B_COMB.seq:*
50: /cgn2_6/ptodata/2/pna/US093C_COMB.seq:*
51: /cgn2_6/ptodata/2/pna/US093D_COMB.seq:*
52: /cgn2_6/ptodata/2/pna/US093E_COMB.seq:*
53: /cgn2_6/ptodata/2/pna/US093F_COMB.seq:*
54: /cgn2_6/ptodata/2/pna/US094A_COMB.seq:*
55: /cgn2_6/ptodata/2/pna/US094B_COMB.seq:*
56: /cgn2_6/ptodata/2/pna/US094C_COMB.seq:*
57: /cgn2_6/ptodata/2/pna/US095_COMB.seq:*
58: /cgn2_6/ptodata/2/pna/US6000_COMB.seq:*
59: /cgn2_6/ptodata/2/pna/US6001A_COMB.seq:*
60: /cgn2_6/ptodata/2/pna/US6001B_COMB.seq:*
61: /cgn2_6/ptodata/2/pna/US6002A_COMB.seq:*
62: /cgn2_6/ptodata/2/pna/US6002B_COMB.seq:*
63: /cgn2_6/ptodata/2/pna/US6002C_COMB.seq:*
64: /cgn2_6/ptodata/2/pna/US6003A_COMB.seq:*
65: /cgn2_6/ptodata/2/pna/US6003B_COMB.seq:*
66: /cgn2_6/ptodata/2/pna/US6004A_COMB.seq:*
67: /cgn2_6/ptodata/2/pna/US6004B_COMB.seq:*
68: /cgn2_6/ptodata/2/pna/US6004C_COMB.seq:*
69: /cgn2_6/ptodata/2/pna/US6005_COMB.seq:*
70: /cgn2_6/ptodata/2/pna/US6006_COMB.seq:*
71: /cgn2_6/ptodata/2/pna/US6007A_COMB.seq:*
72: /cgn2_6/ptodata/2/pna/US6008A_COMB.seq:*
73: /cgn2_6/ptodata/2/pna/US6008B_COMB.seq:*
74: /cgn2_6/ptodata/2/pna/US6008C_COMB.seq:*
75: /cgn2_6/ptodata/2/pna/US6009A_COMB.seq:*
76: /cgn2_6/ptodata/2/pna/US6009B_COMB.seq:*
77: /cgn2_6/ptodata/2/pna/US6010A_COMB.seq:*
78: /cgn2_6/ptodata/2/pna/US6010B_COMB.seq:*
79: /cgn2_6/ptodata/2/pna/US6011A_COMB.seq:*
80: /cgn2_6/ptodata/2/pna/US6011B_COMB.seq:*
81: /cgn2_6/ptodata/2/pna/US6012A_COMB.seq:*
82: /cgn2_6/ptodata/2/pna/US6012B_COMB.seq:*
83: /cgn2_6/ptodata/2/pna/US6013A_COMB.seq:*
84: /cgn2_6/ptodata/2/pna/US6013B_COMB.seq:*
85: /cgn2_6/ptodata/2/pna/US6014A_COMB.seq:*
86: /cgn2_6/ptodata/2/pna/US6014B_COMB.seq:*
87: /cgn2_6/ptodata/2/pna/US6014C_COMB.seq:*
88: /cgn2_6/ptodata/2/pna/US6015_COMB.seq:*
89: /cgn2_6/ptodata/2/pna/US6016A_COMB.seq:*
90: /cgn2_6/ptodata/2/pna/US6016B_COMB.seq:*
91: /cgn2_6/ptodata/2/pna/US6016C_COMB.seq:*
92: /cgn2_6/ptodata/2/pna/US6017A_COMB.seq:*
93: /cgn2_6/ptodata/2/pna/US6017B_COMB.seq:*
94: /cgn2_6/ptodata/2/pna/US6017C_COMB.seq:*
95: /cgn2_6/ptodata/2/pna/US6018A_COMB.seq:*
96: /cgn2_6/ptodata/2/pna/US6018B_COMB.seq:*
97: /cgn2_6/ptodata/2/pna/US6018C_COMB.seq:*
98: /cgn2_6/ptodata/2/pna/US6019_COMB.seq:*
99: /cgn2_6/ptodata/2/pna/PCT_NEW_COMB.seq:*
100: /cgn2_6/ptodata/2/pna/US06_NEW_COMB.seq:*
101: /cgn2_6/ptodata/2/pna/US07_NEW_COMB.seq:*
102: /cgn2_6/ptodata/2/pna/US08_NEW_COMB.seq:*
103: /cgn2_6/ptodata/2/pna/US09_NEW_COMB.seq:*
104: /cgn2_6/ptodata/2/pna/US60_NEW_COMB.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	18	100.0	18	1	PCT-US97-18348-1	Sequence 1, Appl1
2	18	100.0	18	19	US-08-726-211-1	Sequence 1, Appl1
3	18	100.0	20	1	PCT-US94-10725-7	Sequence 7, Appl1

C 4 18 100.0 20 5 US-08-124-256-7 Sequence 7, Appl1
C 5 18 100.0 20 9 US-08-217-082-7 Sequence 7, Appl1
C 6 18 100.0 20 52 US-09-379-718-1 Sequence 1, Appl1
C 7 18 100.0 20 52 US-09-379-718-2 Sequence 2, Appl1
8 18 100.0 20 57 US-09-506-979-1 Sequence 1, Appl1
9 18 100.0 22 14 US-08-403-721-3 Sequence 3, Appl1
10 18 100.0 22 14 US-08-403-721-4 Sequence 4, Appl1
11 18 100.0 22 16 US-08-472-801-304 Sequence 304, App
12 18 100.0 22 18 US-08-668-235-305 Sequence 305, App
C 13 18 100.0 35 1 PCT-US94-10725-2 Sequence 2, Appl1
C 14 18 100.0 35 5 US-08-124-256-2 Sequence 2, Appl1
C 15 18 100.0 35 9 US-08-217-082-2 Sequence 2, Appl1
16 18 100.0 45 16 US-08-472-801-303 Sequence 303, App
17 18 100.0 45 18 US-08-668-235-304 Sequence 304, App
18 17 94.4 19 35 US-09-018-194-7 Sequence 7, Appl1
19 14 77.8 15 57 US-09-506-979-8 Sequence 8, Appl1
20 13.8 76.7 45 54 US-09-404-520-40525 Sequence 40525, A
C 21 13.2 73.3 20 57 US-09-514-000-13846 Sequence 13846, A
22 13.2 72.2 15 57 US-09-506-979-9 Sequence 9, Appl1
23 13 72.2 18 1 PCT-US94-10725-17 Sequence 17, Appl1
24 13 72.2 18 1 PCT-US97-19791-45 Sequence 45, Appl1
25 13 72.2 18 1 PCT-US99-09863-49 Sequence 49, Appl1
26 13 72.2 18 1 PCT-US99-09863-89 Sequence 89, Appl1
27 13 72.2 18 5 US-08-124-256-17 Sequence 17, Appl1
28 13 72.2 18 19 US-08-738-652A-55 Sequence 55, Appl1
29 13 72.2 18 19 US-08-738-652-55 Sequence 55, Appl1
30 13 72.2 18 31 US-08-960-774-45 Sequence 45, Appl1
31 13 72.2 18 36 US-09-030-701-27 Sequence 27, Appl1
32 13 72.2 18 38 US-09-078-954-14 Sequence 14, Appl1
33 13 72.2 18 38 US-09-078-955-14 Sequence 14, Appl1
34 13 72.2 18 40 US-09-108-673A-34 Sequence 34, Appl1
35 13 72.2 18 40 US-09-118-220-1 Sequence 1, Appl1
36 13 72.2 18 42 US-09-191-170-53 Sequence 53, Appl1
37 13 72.2 18 44 US-09-241-653-62 Sequence 62, Appl1
38 13 72.2 18 44 US-09-249-247-218 Sequence 218, App
39 13 72.2 18 46 US-09-248-098-59 Sequence 218, App
40 13 72.2 18 46 US-09-286-098-59 Sequence 59, Appl1
41 13 72.2 18 46 US-09-286-098-104 Sequence 104, App
42 13 72.2 18 48 US-09-306-281-49 Sequence 49, Appl1
43 13 72.2 18 48 US-09-306-281-89 Sequence 89, Appl1
44 13 72.2 18 49 US-09-337-584-45 Sequence 45, Appl1
45 13 72.2 18 102 US-08-923-771B-146 Sequence 146, App

ALIGNMENTS

RESULT 1
PCT-US97-18348-1
; Sequence 1, Application PC/TUS9718348
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: INHIBITION OF Bcl-2 PROTEIN EXPRESSION BY
; TITLE OF INVENTION: LIPOSOMAL ANTISENSE OLIGODEOXYNUCLEOTIDES
; NUMBER OF SEQUENCES: 7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US97/18348
; FILING DATE:
; CLASSIFICATION:
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: US 08/726,211
; FILING DATE: 04-OCT-1996
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

PCT-US97-18348-1
Query Match 100.0%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CACGTCGCCATCTTC 18
|||||
Db 1 CACGTCGCCATCTTC 18

RESULT 2
US-08-726-211-1
; Sequence 1, Application US/08726211
; GENERAL INFORMATION:
; APPLICANT: Tormo, Mar
; APPLICANT: Tati, Ana M.
; TITLE OF INVENTION: INHIBITION OF Bcl-2 PROTEIN EXPRESSION BY
; TITLE OF INVENTION: LIPOSOMAL ANTISENSE OLIGODEOXYNUCLEOTIDES
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: United States of America
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/726,211
; FILING DATE: Concurrently Herewith
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Wilson, Mark B.
; REGISTRATION NUMBER: 37,259
; REFERENCE/DOCKET NUMBER: UTXC:504
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (512) 418-3000
; TELEFAX: (512) 474-7577
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-726-211-1
Query Match 100.0%; Score 18; DB 19; Length 18;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CACGTCGCCATCTTC 18
|||||
Db 1 CACGTCGCCATCTTC 18
RESULT 3
PCT-US94-10725-7/C
; Sequence 7, Application PC/TUS9410725
; GENERAL INFORMATION:
; APPLICANT: Reed, John
; TITLE OF INVENTION: Regulation of bcl-2 Gene Expression
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Gray Cary Ware & Freidenrich
; STREET: 401 B Street, Suite 1700

CITY: San Diego
STATE: CA
COUNTRY: USA
ZIP: 92101-4297
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette 3.5 inch, 1.44 Mb storage
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/10725
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Brotman, Harris F.
REGISTRATION NUMBER: 35461
REFERENCE/DOCKET NUMBER: P0040M01
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619) 699-3630
TELEFAX: (619) 236-1048
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
ANTI-SENSE: NO
PCT-US94-10725-7

Query Match 100.0%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CAGCGTGGCCATCCTTC 18
|||||
Db 20 CAGCGTGGCCATCCTTC 3

RESULT 4
US-08-124-256-7/c
Sequence 7, Application US/08124256
GENERAL INFORMATION:
APPLICANT: Reed, John
TITLE OF INVENTION: Regulation of bcl-2 Gene Expression
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESS:
ADDRESSEE: Gray, Cary, Ames & Frye
STREET: 401 B Street, Suite 1700
CITY: San Diego
STATE: CA
COUNTRY: USA
ZIP: 92101-4297
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/124,256
FILING DATE:
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Brotman, Harris F.
REGISTRATION NUMBER: 35461
REFERENCE/DOCKET NUMBER: P0041US0
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619) 699-3630
TELEFAX: (619) 236-1048
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs

TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
ANTI-SENSE: NO
US-08-124-256-7

Query Match 100.0%; Score 18; DB 5; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CAGCGTGGCCATCCTTC 18
|||||
Db 20 CAGCGTGGCCATCCTTC 3

RESULT 5
US-08-217-082-7/c
Sequence 7, Application US/08217082
GENERAL INFORMATION:
APPLICANT: John Reed
TITLE OF INVENTION: Antisense Oligonucleotides For
TITLE OF INVENTION: Inhibiting the Growth of Cells Expressing the
NUMBER OF SEQUENCES: 16
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz
ADDRESSEE: Mackiewicz & Norris
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: USA
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/217,082
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/07/840,716
FILING DATE:
APPLICATION NUMBER: 288,692
FILING DATE: December 22, 1988
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: UPN-0906
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
ANTI-SENSE: NO
US-08-217-082-7

Query Match 100.0%; Score 18; DB 9; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CAGCGTGGCCATCCTTC 18
|||||
Db 20 CAGCGTGGCCATCCTTC 3

RESULT 6
US-09-379-718-1
; Sequence 1, Application US/09379718
; GENERAL INFORMATION:
; APPLICANT: Farrell, Nicholas
; TITLE OF INVENTION: High Affinity DNA Binding Compounds as Adjuvants in
; FILE REFERENCE: farrell/kloster
; CURRENT APPLICATION NUMBER: US/09/379,718
; CURRENT FILING DATE: 1999-08-24
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: Patentln Ver. 2.1
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic
US-09-379-718-1

Query Match 100.0%; Score 18; DB 52; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CAGCGTGGCCCATCCCTTC 18
|||||
DB 1 cagcgtgcccacatcccttc 18

RESULT 7
US-09-379-718-2/c
; Sequence 2, Application US/09379718
; GENERAL INFORMATION:
; APPLICANT: Farrell, Nicholas
; APPLICANT: Kloster, Miriam
; TITLE OF INVENTION: High Affinity DNA Binding Compounds as Adjuvants in
; FILE REFERENCE: farrell/kloster
; CURRENT APPLICATION NUMBER: US/09/379,718
; CURRENT FILING DATE: 1999-08-24
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: Patentln Ver. 2.1
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic
US-09-379-718-2

Query Match 100.0%; Score 18; DB 52; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGCGTGGCCCATCCCTTC 18
|||||
DB 20 CAGCGTGGCCCATCCCTTC 3

RESULT 8
US-09-506-979-1
; Sequence 1, Application US/09506979
; GENERAL INFORMATION:
; APPLICANT: TARI, ANA M.
; APPLICANT: LOPEZ-BERESPEIN, GABRIEL
; APPLICANT: GUTIERREZ-PUENTE, YOLANDA
; TITLE OF INVENTION: SMALL OLIGONUCLEOTIDES WITH ANTI-TUMOR ACTIVITY

; FILE REFERENCE: UTXC619
; CURRENT APPLICATION NUMBER: US/09/506,979
; CURRENT FILING DATE: 2000-02-18
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: Patentln Ver. 2.1
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-506-979-1

Query Match 100.0%; Score 18; DB 57; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CAGCGTGGCCCATCCCTTC 18
|||||
DB 1 cagcgtgcccacatcccttc 18

RESULT 9
US-08-403-721-3
; Sequence 3, Application US/08403721
; GENERAL INFORMATION:
; APPLICANT: EVAN, Gerald Ian
; TITLE OF INVENTION: Modified Cells And Methods Of Treatment
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HALE AND DORR
; STREET: 1455 Pennsylvania Avenue, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC Compatible
; SOFTWARE: Patentln Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/403,721
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/GB93/00686
; FILING DATE: 02 APRIL 1993
; ATTORNEY/AGENT INFORMATION:
; NAME: HENRY N. WIXON
; REFERENCE/DOCKET NUMBER: 104322.139
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 942-8400
; TELEFAX: (202) 942-8484
; TELEX:
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA to mRNA
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
US-08-403-721-3

Query Match 100.0%; Score 18; DB 14; Length 22;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

NAME: Brotman, Harris F.
REGISTRATION NUMBER: 35461
REFERENCE/DOCKET NUMBER: P0040M01
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619) 699-3630
TELEFAX: (619) 236-1048
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 35 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
ANTI-SENSE: NO
PCT-US94-10725-2

Query Match 100.0%; Score 18; DB 1; Length 35;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CACGTCGCCCATCTTC 18
|||||
DB 30 CACGTCGCCCATCTTC 13

RESULT 14
US-08-124-256-2/C
Sequence 2, Application US/08124256
GENERAL INFORMATION:
APPLICANT: Reed, John
TITLE OF INVENTION: Regulation of bcl-2 Gene Expression
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESS:
ADDRESSEE: Gray, Cary, Ames & Frye
STREET: 401 B Street, Suite 1700
CITY: San Diego
STATE: CA
COUNTRY: USA
ZIP: 92101-4297
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/124,256
FILING DATE:
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Brotman, Harris F.
REGISTRATION NUMBER: 35461
REFERENCE/DOCKET NUMBER: P0041US0
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619) 699-3630
TELEFAX: (619) 236-1048
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 35 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
ANTI-SENSE: NO
US-08-124-256-2

Query Match 100.0%; Score 18; DB 5; Length 35;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CACGTCGCCCATCTTC 18
|||||

DB 30 CACGTCGCCCATCTTC 13

RESULT 15
US-08-217-082-2/C
Sequence 2, Application US/08217082
GENERAL INFORMATION:
APPLICANT: John Reed
TITLE OF INVENTION: Antisense Oligonucleotides For
Inhibiting the Growth of Cells Expressing the
TITLE OF INVENTION: Human bcl-2 gene
NUMBER OF SEQUENCES: 16
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz
ADDRESSEE: Mackiewicz & Norris
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: USA
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/217,082
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/07/840,716
FILING DATE:
APPLICATION NUMBER: 288,692
FILING DATE: December 22, 1988
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: UPN-0906
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 35
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
ANTI-SENSE: NO
US-08-217-082-2

Query Match 100.0%; Score 18; DB 9; Length 35;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CACGTCGCCCATCTTC 18
|||||
DB 30 CACGTCGCCCATCTTC 13

Search completed: June 18, 2000, 21:25:09
Job time: 3270 sec

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 Comugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 18, 2000, 18:33:40 ; Search time 525.5 Seconds
(without alignments)
138.835 Million cell updates/sec

Title: PCT-US97-18348-1
Perfect score: 18
Sequence: 1 CAGCGTGGCCATCCTTC 18

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 4857316 seqs, 202661650 residues

Total number of hits satisfying chosen parameters: 23194

Minimum DB seq length: 0
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Listing first 45 summaries

Database :

EST: *
1: em_est1:*
2: em_est2:*
3: em_est3:*
4: em_est4:*
5: em_est5:*
6: em_est6:*
7: em_est7:*
8: em_est8:*
9: em_est9:*
10: em_est10:*
11: em_est11:*
12: em_est12:*
13: em_est13:*
14: em_est14:*
15: em_est15:*
16: em_est16:*
17: em_est17:*
18: em_est18:*
19: em_est19:*
20: gb_est1:*
21: gb_est2:*
22: gb_est3:*
23: gb_est4:*
24: gb_est5:*
25: gb_est6:*
26: gb_est7:*
27: gb_est8:*
28: gb_est9:*
29: gb_est10:*
30: gb_est11:*
31: gb_est12:*
32: gb_est13:*
33: gb_est14:*
34: gb_est15:*
35: gb_est16:*
36: gb_est17:*
37: gb_est18:*
38: gb_est19:*
39: gb_est20:*
40: gb_est21:*
41: gb_est22:*
42: gb_est23:*
43: gb_est24:*
44: gb_est25:*

45: gb_est26:*
46: gb_est27:*
47: gb_est28:*
48: gb_est29:*
49: gb_est30:*
50: gb_est31:*
51: gb_est32:*
52: em_est20:*
53: em_est21:*
54: em_est22:*
55: em_est23:*
56: em_est24:*
57: em_est25:*
58: em_est26:*
59: gb_est33:*
60: gb_est34:*
61: gb_est35:*
62: gb_est36:*
63: gb_est37:*
64: gb_est38:*
65: em_est27:*
66: em_est28:*
67: em_est29:*
68: em_est30:*
69: gb_est39:*
70: gb_est40:*
71: gb_est41:*
72: gb_est42:*
73: gb_est43:*
74: gb_est44:*
75: em_est31:*
76: em_est32:*
77: em_est33:*
78: em_est34:*
79: gb_est45:*
80: gb_est46:*
81: gb_est47:*
82: gb_gss1:*
83: gb_gss2:*
84: gb_gss3:*
85: gb_gss4:*
86: em_gss1:*
87: em_gss2:*
88: em_gss3:*
89: em_gss4:*
90: gb_gss5:*
91: gb_gss6:*
92: gb_gss7:*
93: gb_gss8:*
94: gb_gss9:*
95: em_gss5:*
96: em_gss6:*
97: em_gss7:*
98: em_gss8:*
99: em_gss9:*
100: em_gss10:*
101: em_gss11:*
102: gb_gss10:*
103: gb_gss11:*
104: em_gss12:*
105: gb_gss12:*
106: gb_gss13:*
107: gb_gss14:*
108: gb_gss15:*
109: gb_gss16:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result Query

No.	Score	Match	Length	DB	ID	Description
C 1	11.8	65.6	25	40	AA961707	AA961707 or40e08.s
C 2	11.6	64.4	41	37	AA680963	AA680963 lmfRam057
C 3	10.8	60.0	35	23	H53677	H53677 yu38f01.r1
C 4	10.8	60.0	43	41	AI038493	AI038493 ox38a09.s
C 5	10.8	60.0	49	20	TI1453	TI1453 CHR90019.ch
C 6	10.6	58.9	37	43	AI188871	AI188871 qd27b11.x
C 7	10.2	56.7	31	46	AI459772	AI459772 ac03c06.x
C 8	10.2	56.7	40	46	AI459438	AI459438 ar01b11.x
C 9	10.2	56.7	43	36	AA654543	AA654543 nt59d05.s
C 10	10.2	56.7	43	40	AI000393	AI000393 ct06e05.s
C 11	10.2	56.7	46	39	AA854777	AA854777 aj77b02.s
C 12	10	55.6	31	39	AA868659	AA868659 ak49g02.s
C 13	10	55.6	41	34	AA509356	AA509356 vg18a09.r
C 14	10	55.6	45	94	AA025518	AA025518 EP(X)1587
C 15	10	55.6	49	44	AI254752	AI254752 gt89f07.x
C 16	10	55.6	49	49	AI628197	AI628197 ly22f08.x
C 17	9.8	54.4	26	94	AA025266	AA025266 EP(3)3084
C 18	9.8	54.4	28	48	AI625245	AI625245 ts42e06.x
C 19	9.8	54.4	34	26	W24112	W24112 zb48h04.r1
C 20	9.8	54.4	37	38	AA808573	AA808573 cb38b02.s
C 21	9.8	54.4	37	82	HSMC09A10	H88437 H.sapiens.D
C 22	9.8	54.4	40	30	AA226145	AA226145 nc09f09.r
C 23	9.8	54.4	43	30	AA231183	AA231183 mw31f06.r
C 24	9.8	54.4	48	21	T61673	T61673 yb87g04.s1
C 25	9.6	53.3	34	40	AA971412	AA971412 op92c11.s
C 26	9.6	53.3	34	47	AI528944	AI528944 ud43c06.y
C 27	9.6	53.3	37	39	AA867149	AA867149 vx23h09.r
C 28	9.6	53.3	40	24	H99190	H99190 yx15d07.s1
C 29	9.6	53.3	43	40	AA948558	AA948558 on68d08.s
C 30	9.6	53.3	43	44	AI282449	AI282449 qv04c12.x
C 31	9.6	53.3	46	37	AA719000	AA719000 zh22h04.s
C 32	9.6	53.3	46	38	AA795140	AA795140 vg94b01.r
C 33	9.6	53.3	49	38	AA813812	AA813812 ai72c08.s
C 34	9.6	53.3	49	44	AI246743	AI246743 qk40c09.x
C 35	9.6	53.3	49	44	AI020003	AI020003 ua95h03.r
C 36	9.4	52.2	34	41	AI020003	AI020003 ua95h03.r
C 37	9.4	52.2	37	39	AA889248	AA889248 ak26d11.s
C 38	9.4	52.2	40	41	AI027584	AI027584 ow4a04.x
C 39	9.4	52.2	43	22	H09843	H09843 ym01d05.r1
C 40	9.4	52.2	43	33	AA433628	AA433628 vf47d01.r
C 41	9.4	52.2	46	23	H49581	H49581 y023b02.s1
C 42	9.4	52.2	46	34	AA455514	AA455514 zx77g01.s
C 43	9.4	52.2	47	23	R85311	R85311 y039d07.r1
C 44	9.4	52.2	49	26	W40572	W40572 zc79e12.r1
C 45	9.2	51.1	27	22	AA233183	AA233183 zrg6f08.s
					R23703	R23703 yh35e11.r1

ALIGNMENTS

RESULT 1
AA961707/c
LOCUS
DEFINITION
AA961707 25 bp mRNA
or40e08.s1 NCI_CGAP.GC3 Homo sapiens cDNA clone IMAGE:1598342 3'
similar to SW:SN24.HUMAN P51532 POSSIBLE GLOBAL TRANSCRIPTION
ACTIVATOR SNF2L4 ; contains TARI.t2 TARI repetitive element ; , mRNA
sequence.

ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
AA961707.1 GI:3133871
EST.
human.
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT
NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
Unpublished (1997)
On Sep 12, 1996 this sequence version replaced gi:1407458.
Contact: Robert Strausberg, Ph.D.

Tel: (301) 496-1550
Email: Robert.Strausberg@nih.gov
Tissue Procurement: Christopher A. Moskaluk, M.D., Ph.D., Michael
Emmett-Buck, M.D., Ph.D.
CDNA Library Preparation: M. Bento Soares, Ph.D.
CDNA Library Arrayed by: Greg Lennon, Ph.D.
DNA Sequencing by: Washington University Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
www.bio.llnl.gov/bbrp/image/image.html

FEATURES

source

Insert Length: 388 Std Error: 0.00
Seq primer: -40m13 fwd. Et from Amersham
High quality sequence stop: 1.
Location/Qualifiers

1..25

/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:1598342"
/clone_lib="NCI_CGAP_GC3"
/tissue_type="pooled germ cell tumors"
/lab_host="DH10B"

/note="Vector: pRTT3D-Pac (Pharmacia) with a modified
polylinker: 1st strand cDNA was prepared from 3 pooled
germ cell tumors, and was then primed with a Not I -
oligo(dT) primer. Double-stranded cDNA was ligated to Eco
RI adaptors (Pharmacia), digested with Not I and cloned
into the Not I and Eco RI sites of the modified pRTT3
vector. Library is not normalized. Library was
constructed by Bento Soares and M. Fatima Bonaldo."

BASE COUNT
4 a 7 c 10 g 4 t

Query Match
Best Local Similarity 65.6% Score 11.8; DB 40; Length 25;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
1 CAGCGTGGCCATCC 15
||||||| 11 11
24 CAGCGTGGCCATCC 10

RESULT 2
AA680963/c
LOCUS
DEFINITION
AA680963 41 bp mRNA
lmfRam0579 Leishmania major Amastigote Lambda zap II library
Leishmania major cDNA clone S07 5', mRNA sequence.
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
AA680963.1 GI:2662968
EST.
Leishmania major.
Leishmania major.
Eukaryota; Euzlenozoa; Kinetoplastida; Trypanosomatidae;
Leishmania.

REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT
1 (bases 1 to 41)
Norris,A.R., Dyall,S.D., Smith,D.F. and Blackwell,J.M.
Analysis of Leishmania Major Amastigote Expressed Sequence Tags
Unpublished (1997)
On Sep 12, 1997 this sequence version replaced gi:2264545.
Contact: Blackwell JM
Cambridge Institute for Medical Research
Wellcome Trust/MRC Building, Addenbrooke's Hospital, Hills Road,
Cambridge CB2 2XY, UK
Tel: 01223 336 143
Fax: 01223 331 206
Email: jmb37@cus.cam.ac.uk

PCR Primers
FORWARD: GTAAACGACGCGCAGT
BACKWARD: GGAACAGCATGACCATG
Seq primer: AATTACCTCCTCAAGG
High quality sequence stop: 41.
Location/Qualifiers

```
source
1. .41
/organism="Leishmania major"
/strain="Friedlin"
/db_xref="taxon:5664"
/clone="507"
/clone_1lb="Leishmania major Amastigote Lambda Zap II
library"
/cell_type="Amastigote"
/notes="Vector: Lambda Zap II; Site_1: XhoI; Site_2: NotI"
BASE COUNT      9 a      14 c      8 g      10 t
ORIGIN

Query Match      64.4%; Score 11.6; DB 37; Length 41;
Best Local Similarity 77.8%; Pred. No. 1.9e+04;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY      1 CAGCGTGGCCATCCTTC 18
      ||| ||||| ||| |||
Db      29 CAGGTGGCGACATGATTC 12

RESULT 3
H53677      35 bp      mRNA      EST      20-SEP-1995
LOCUS      YU38F01.r1 Soares ovary tumor NBHOR Homo sapiens cDNA clone
DEFINITION IMAGE:236089 5' similar to gb:X01683 ALPHA-1-ANTITRYPSIN PRECURSOR
(HUMAN);, mRNA sequence.
ACCESSION H53677      GI:993824
VERSION H53677      EST.
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1 (bases 1 to 35)
AUTHORS Hillier, L., Lennon, G., Becker, M., Bonaldo, M.F., Chiapelli, B.,
Chissoe, S., Dietrich, N., Dubuque, T., Favello, A., Gish, W.,
Hawkins, M., Hultman, M., Kucaba, T., Lacy, M., Le, M., Le, N.,
Mardis, E., Moore, B., Morris, M., Parsons, D., Prange, C., Rifkin, L.,
Rohtling, T., Schellenberg, K., Soares, M.B., Tan, F., Thierry-Mieg, J.,
Treviskus, E., Underwood, K., Wohlmann, P., Waterston, R., Wilson, R.,
and Marra, M.
Generation and analysis of 280,000 human expressed sequence tags
TITLE Genome Res. 6 (9), 807-828 (1996)
JOURNAL 97044478
MEDLINE On May 8, 1995 this sequence version replaced gi:800757.
COMMENT Contact: Wilson RK
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu
Insert Size: 1505
High quality sequence starts: 1
High quality sequence stops: 1
Source: IMAGE Consortium, LML
This clone is available royalty-free through LML; contact the
IMAGE Consortium (info@image.lml.gov) for further information.
Trace considered overall poor quality
Insert Length: 1505 Std Error: 0.00
Seq primer: M13Rp1
High quality sequence stop: 1.
FEATURES
Location/Qualifiers
1. .35
/organism="Homo sapiens"
/db_xref="GDB:3863008"
/db_xref="taxon:9606"
/clone="IMAGE:236089"
/clone_1lb="Soares ovary tumor NBHOR"
/sex="Female"
/tissue_type="ovarian tumor"
/lab_host="DH10B (ampicillin resistant)"
```

```
/note="Organ: ovary; Vector: pT73D (Pharmacia) with a
modified polylinker; Site_1: Not I; Site_2: Eco RI; 1st
strand cDNA was primed with a Not I - oligo(dT) primer [5'
TGTTCACCAATCTGAAGTGGAGCGCGCGTATTTTATTTTATTTT 3'],
double-stranded cDNA was size selected, ligated to Eco RI
adapters (Pharmacia), digested with Not I and cloned into
the Not I and Eco RI sites of a modified pT73 vector
(Pharmacia). Library constructed by Bento Soares and
M. Fatima Bonaldo."
BASE COUNT      3 a      11 c      9 g      11 t      1 others
ORIGIN

Query Match      60.0%; Score 10.8; DB 23; Length 35;
Best Local Similarity 80.0%; Pred. No. 4.5e+04;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      4 CGTGGCCATCCTTC 18
      ||| | ||||| |
Db      19 CGTGGCGCATCTTC 33

RESULT 4
A1038493      43 bp      mRNA      EST      24-SEP-1998
LOCUS      OX38A09.s1 Soares-total_fetus_NB2HP8_9w Homo sapiens cDNA clone
DEFINITION IMAGE:1658584 3' similar to TR:041707 Q41707 EXTENSIN CLASS 1
PROTEIN PRECURSOR., mRNA sequence.
ACCESSION A1038493
VERSION A1038493      GI:3277687
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1 (bases 1 to 43)
AUTHORS NCI-CCG http://www.ncbi.nlm.nih.gov/ccgacp.
TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
JOURNAL Unpublished (1997)
COMMENT On May 5, 1995 this sequence version replaced gi:797645.
Contact: Robert Strausberg, Ph.D.
Tel: (301) 496-1550
Email: Robert.Strausberg@nih.gov
This clone is available royalty-free through LML; contact the
IMAGE Consortium (info@image.lml.gov) for further information.
Trace considered overall poor quality
Insert Length: 332 Std Error: 0.00
Seq primer: -40m13 fwd. ET from Amersham
High quality sequence stop: 1.
FEATURES
Location/Qualifiers
1. .43
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:1658584"
/clone_1lb="Soares-total_fetus_NB2HP8_9w"
/dev_stage="8-9 weeks"
/lab_host="DH10B"
/notes="Vector: pT73D-Pac (Pharmacia) with a modified
polylinker; Site_1: Not I; Site_2: Eco RI; 1st strand cDNA
was prepared from mRNA obtained from pooled 8-9 week
(total) fetus material with a Not I - oligo(dT) primer [5'
TGTTCACCAATCTGAAGTGGAGCGCGCGTATTTTATTTTATTTT 3'].
Double-stranded cDNA was ligated to Eco RI adapters
(Pharmacia), digested with Not I and cloned into the Not I
and Eco RI sites of the modified pT73 vector. Library
went through one round of normalization, and was
constructed by Bento Soares and M. Fatima Bonaldo. "
```

Query Match

60.0%; Score 10.8; DB 41; Length 43;

Best Local Similarity 85.7%; Pred. No. 4.8e+04;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 4 CGGCGGCCACCTT 17
||||| ||||| |||
Db 14 CGTGCTCCATCGTT 1

RESULT 5
T11453 49 bp DNA EST 30-NOV-1993
LOCUS T11453/c
DEFINITION CHR9019 Chromosome 9 exon Homo sapiens genomic clone 34B-5.5 and
3', mRNA sequence.
ACCESSION T11453
VERSION T11453.1 GI:430876
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE 1 (bases 1 to 49)
AUTHORS Church,D.M., Banks,L.T., Rogers,A.C., Graw,S.L., Housman,D.E.,
Gusella,J.F. and Buckler,A.J.
TITLE Identification of human chromosome 9 specific genes using exon
amplification
JOURNAL Hum. Mol. Genet. 2, 1915-1920 (1993)
MEDLINE 94108448
COMMENT Contact: Buckler AJ
Molecular Neurogenetics Unit
Massachusetts General Hospital
Building 149, 13th St., Charlestown MA 02129
Tel: 6177249616
Fax: 6177265736
Email: buckler@helix.mgh.harvard.edu
Seq primer: T3 and T7

FEATURES
source
1.49
Location/Qualifiers
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="34B-5"
/clone_lib="Chromosome 9 exon"
/lab_host="E. coli DH5a"
/note="Vector: pBluescript+; Exons were isolated from
human chromosome 9 specific cosmids using the method of
88:4005-4009, 1991). Exons were cloned into
pBluescript+ converted to T vector at the EcoRV site.

BASE COUNT 14 a 6 c 18 g 11 t

ORIGIN

Query Match 60.0%; Score 10.8; DB 20; Length 49;
Best Local Similarity 85.7%; Pred. No. 4.9e+04;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1 CACGCTGCGCCATC 14
||||| ||||| |||||
Db 19 CAGCTTGCTCCATC 6

RESULT 6
A118871 37 bp mRNA EST 13-OCT-1998
LOCUS A118871
DEFINITION qd27b11.x1 Soares placenta.8to9weeks.2NHP8to9w Homo sapiens cDNA
clone IMAGE:1724925.3 similar to SW:FOR2_HUMAN P45880
VOLTAGE-DEPENDENT ANION-SELECTIVE CHANNEL PROTEIN 2 ; mRNA
sequence.
ACCESSION A118871
VERSION A118871.1 GI:3740080
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE 1 (bases 1 to 37)
AUTHORS NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.
TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
JOURNAL Unpublished (1997)
COMMENT Contact: Robert Strausberg, Ph.D.
Tel: (301) 496-1550
Email: Robert.Strausberg@nih.gov
This clone is available royalty-free through LNL; contact the
IMAGE Consortium (info@image.lnl.gov) for further information.
Trace considered overall poor quality
Seq primer: -40UP from G4bc
High quality sequence stop: 1.
Location/Qualifiers
1.37
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:1724925"
/clone_lib="Soares placenta.8to9weeks.2NHP8to9w"
/dev_stage="two placenta; one from 8 weeks and another
from 9 weeks post conception"
/lab_host="DH10B (ampicillin resistant)"
/note="Organ: Placenta; Vector: pTV73D (Pharmacia) with a
modified polylinker; Site-1: Not I; Site-2: Eco RI; 1st
strand cDNA was primed with a Not I - oligo(dT) primer [5'
GTTCACATCTGACAGTGGAGCGGCGGATTTTCTTTTCTTTT 3']
double-stranded cDNA was size selected, ligated to Eco RI
adapters (Pharmacia), digested with Not I and cloned into
the Not I and Eco RI sites of a modified pTV73 vector
(Pharmacia). Library constructed by Bento Soares and
M.Fatima Bonaldo."

BASE COUNT 8 a 12 c 9 g 8 t

ORIGIN

Query Match 58.9%; Score 10.6; DB 43; Length 37;
Best Local Similarity 76.5%; Pred. No. 5.7e+04;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY 1 CACGCTGCGCCACCTT 17
||||| ||||| |||||
Db 15 CACGCGCGACCCACCTT 31

RESULT 7
A1459772/c 31 bp mRNA EST 09-MAR-1999
LOCUS A1459772
DEFINITION ao93c06.x1 Schiller meninglioma Homo sapiens cDNA clone
IMAGE:1953418.3 similar to SW:NUBM_BOVIN P25708 NMDH-UBIQUINONE
OXIDOREDUCTASE 51 KD SUBUNIT PRECURSOR ; mRNA sequence.
ACCESSION A1459772
VERSION A1459772.1 GI:4312653
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE 1 (bases 1 to 31)
AUTHORS Hillier,L., Allen,M., Bowles,L., Dubuque,T., Getsel,G., Jost,S.,
Krizman,D., Kucaba,T., Lacy,M., Le,N., Lennon,G., Marra,M.,
Martin,J., Moore,B., Schellenberg,K., Steptoe,M., Tan,F.,
Theising,B., White,Y., Wyllie,T., Waterston,R. and Wilson,R.
TITLE WashU-MCI human EST Project
JOURNAL Unpublished (1997)
COMMENT On Jun 5, 1998 this sequence version replaced g1:3188933.
Contact: Wilson RK
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@wustl.wustl.edu

/lab_host="DH10B"
 /note="Vector: PAMPI0, site_1: NotI, site_2: EcoRI; 1st strand cDNA was primed with oligo(dT)17 on 50 ng of DNase-treated, total cellular RNA obtained from 5,000-10,000 microdissected cells histologically determined to be fully malignant prostate cancer cells. Double-stranded cDNA was ligated to EcoRI adaptors, 5 cycles of PCR applied to the cDNA with an adaptor-specific primer, and the resulting PCR product subcloned into PAMPI0 by the UNC-cloning method (Life Technologies). Average insert size is 600 bp. NOTE: Not directionally cloned. This library was constructed by David Krizman."

BASE COUNT
 ORIGIN
 8 a 11 c 12 g 12 t

Query Match 56.7%; Score 10.2; DB 36; Length 43;
 Best Local Similarity 80.0%; Pred. No. 9.4e+04;
 Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 CAGCGTGGCCATCC 15
 ||||| ||||| |
 Db 22 CAGCTGCTCATAC 8

RESULT 10
 AI000393 43 bp mRNA EST 13-FEB-1999
 LOCUS ot0605.s1 NCI_CGAP_GC3 Homo sapiens cDNA clone IMAGE:1614080 3'
 DEFINITION similar to TR:00409 000409 CHECKPOINT SUPPRESSOR 1.; mRNA sequence.
 ACCESSION AI000393
 VERSION AI000393.1 GI:3190947
 KEYWORDS EST.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
 1 (bases 1 to 43)
 NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
 National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index
 Unpublished (1997)
 On Jan 17, 1998 this sequence version replaced gi:2044803.
 Contact: Robert Strausberg, Ph.D.
 Tel: (301) 496-1550
 Email: Robert.Strausberg@nih.gov
 Tissue Procurement: Christopher A. Moskaluk, M.D., Ph.D., Michael Emmert-Buck, M.D., Ph.D.
 CDNA Library Preparation: M. Bento Soares, Ph.D.
 CDNA Library Arrayed by: Greg Lennon, Ph.D.
 DNA Sequencing by: Washington University Genome Sequencing Center
 Clone distribution: NCI-CGAP clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: www.bio.llnl.gov/bbrp/image/image.html

Trace considered overall poor quality
 Insert length: 1173 Std Error: 0.00
 Seq primer: -40m13 fwd. ET from Amersham
 High quality sequence stop: 1.
 Location/Qualifiers
 1. 43
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="IMAGE:1614080"
 /clone_lib="NCI_CGAP_GC3"
 /tissue_type="pooled germ cell tumors"
 /lab_host="DH10B"
 /note="Vector: PT73D-Pac (Pharmacia) with a modified polylinker; 1st strand cDNA was prepared from 3 pooled germ cell tumors, and was then primed with a Not I - oligo(dT) primer. Double-stranded cDNA was ligated to Eco

RI adaptors (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of the modified pT73 vector. Library is not normalised. Library was constructed by Bento Soares and M. Fatima Bonaldo."

BASE COUNT
 ORIGIN
 7 a 12 c 15 g 9 t

Query Match 56.7%; Score 10.2; DB 40; Length 43;
 Best Local Similarity 80.0%; Pred. No. 9.4e+04;
 Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2 AGCGTGGCCATCCT 16
 ||||| ||||| |
 Db 21 AGAGTGAGCCATCTT 35

RESULT 11
 AA854777 46 bp mRNA EST 04-JAN-1999
 LOCUS a177b02.s1 Soares parathyroid tumor NBHPA Homo sapiens cDNA clone
 DEFINITION IMAGE:1402443 3', similar to TR:Q14264 Q14264 ENVELOPE PROTEIN.
 ; contains LTR2.c3 LTR2 repetitive element.; mRNA sequence.
 ACCESSION AA854777
 VERSION AA854777.1 GI:2942315
 KEYWORDS EST.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
 1 (bases 1 to 46)
 NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
 National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index
 Unpublished (1997)
 On Jan 17, 1998 this sequence version replaced gi:2043498.
 Contact: Robert Strausberg, Ph.D.
 Tel: (301) 496-1550
 Email: Robert.Strausberg@nih.gov
 CDNA Library Preparation: M. Bento Soares, Ph.D., M. Fatima Bonaldo, Ph.D.
 CDNA Library Arrayed by: Greg Lennon, Ph.D.
 DNA Sequencing by: Washington University Genome Sequencing Center
 Clone distribution: NCI-CGAP clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: www.bio.llnl.gov/bbrp/image/image.html

Trace considered overall poor quality
 Possible reversed clone: similarity on wrong strand
 Insert length: 1357 Std Error: 0.00
 Seq primer: -40m13 fwd. ET from Amersham
 High quality sequence stop: 1.
 Location/Qualifiers
 1. 46
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="IMAGE:1402443"
 /clone_lib="Soares parathyroid tumor_NBHPA"
 /tissue_type="parathyroid tumor"
 /dev_stage="adult"
 /lab_host="parathyroid tumor"
 /note="Organ: parathyroid gland; Vector: pT73D (Pharmacia) with a modified polylinker; Site_1: Not I; Site_2: Eco RI; 1st strand cDNA was primed with a Not I - oligo(dT) primer

15-
 TGTACCAATCTGAAGTGGAGCGCCGACCAATTTTTTTTTTTTTTTTTTTT
 T-3'], double-stranded cDNA was size selected, ligated to Eco RI adaptors (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of a modified pT73 vector (Pharmacia). Library went through one round of normalization to a Cot = 5. Library constructed by Bento Soares and M. Fatima Bonaldo. RNA from sporadic parathyroid

adenomas was kindly provided by Dr. Stephen Marx, National Institute of Diabetes and Digestive and Kidney Diseases, NIH."

BASE COUNT 10 a 16 c 11 g 9 t

ORIGIN

Query Match 56.7%; Score 10.2; DB 39; Length 46;
Best Local Similarity 80.0%; Pred. No. 9.6e+04;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1 CAGCGTGGCCATCC 15
|||||
Db 31 CAGCGAGAGCGGCTCC 45

RESULT 12

AA868659 31 bp mRNA EST 16-MAR-1998
LOCUS AK49902.s1 Soares_testis_NHT Homo sapiens CDNA clone IMAGE:1409330
DEFINITION 3' similar to TR:014957.014957 SMALLEST SUBUNIT OF
UBIQUINOL-CYTOCHROME C REDUCTASE.; mRNA sequence.

ACCESSION AA868659.1 GI:2964104
VERSION AA868659.1
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
AUTHORS Eutheria; Primates; Catarrhini; Homiidae; Homo.
1 (bases 1 to 31)
TITLE NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index

JOURNAL Unpublished (1997)
COMMENT On Jan 19, 1998 this sequence version replaced gi:2152319.
Contact: Robert Strausberg, Ph.D.
Tel: (301) 496-1550

Email: Robert.Strausberg@nih.gov
CDNA Library Preparation: M. Bento Soares, Ph.D., M. Fatima Bonaldo, Ph.D.
CDNA Library Arrayed by: Greg Lennon, Ph.D.
DNA Sequencing by: Washington University Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
www-bio.llnl.gov/dbp/image/image.html

Trace considered overall poor quality
Possible reversed clone: similarity on wrong strand
Seq primer: -40ml3 fwd. ET from Amersham
High quality sequence stop: 1.
Location/Qualifiers

FEATURES

Source

1. 31
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:1409330"
/clone_1b="Soares_testis_NHT"
/sex="male"
/lab_host="DH10B"
/note="Vector: pT73D-Pac (Pharmacia) with a modified
polylinker; Site 1: Not I; Site 2: Eco RI; 1st strand CDNA
was prepared from mRNA obtained from Clontech
Laboratories, Inc., and primed with a Not I - oligo(dT)
primer [5'
TGTTCACCAATCTGACGTGAGCGCGCCCAATTTTTTTTTTTT 3']
Double-stranded CDNA was ligated to Eco RI adaptors
(Pharmacia), digested with Not I and cloned into the Not I
and Eco RI sites of the modified pT73 vector. Library
went through one round of normalization to Cot5, and was
constructed by Bento Soares and M. Fatima Bonaldo."

BASE COUNT 6 a 10 c 10 g 5 t

ORIGIN

Query Match 55.6%; Score 10; DB 39; Length 31;
Best Local Similarity 100.0%; Pred. No. 1.1e+05;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2 AGCGTGGCCC 11
|||||
Db 4 AGCGTGGCCC 13

RESULT 13
AA509356/c 41 bp mRNA EST 08-JUL-1997
LOCUS VG18a09.r1 Soares mouse NBMH Mus musculus CDNA clone IMAGE:861688
DEFINITION 5' similar to gb:M27034 Mouse MHC class I D-region cell surface
antigen (MOUSE);, mRNA sequence.

ACCESSION AA509356.1 GI:2247210
VERSION AA509356
KEYWORDS EST.
SOURCE house mouse.
ORGANISM Mus musculus

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
AUTHORS Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 41)

Geisel,S., Kucaba,T., Lacy,M., Le,M., Martin,J., Morris,M.,
Schellenberg,K., Steptoe,M., Tan,F., Underwood,K., Moore,B.,
Theising,B., Wylie,T., Lennon,G., Soares,B., Wilson,R. and
Waterston,R.
The WashU-HMI Mouse EST Project
Unpublished (1996)

JOURNAL On Sep 12, 1996 this sequence version replaced gi:1405263.
COMMENT Contact: Marra M/Mouse Est Project
WashU-HMI Mouse EST Project
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810

Email: mouseest@wustl.edu
This clone is available royalty-free through LLNL; contact the
IMAGE Consortium (info@image.llnl.gov) for further information.
MGI:505776

Trace considered overall poor quality
Seq primer: -28ml3 rev2 ET from Amersham
High quality sequence stop: 1.
Location/Qualifiers

FEATURES

Source

1. 41
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="IMAGE:861688"
/clone_1b="Soares mouse NBMH"
/sex="male"
/tissue_type="heart"
/dev_stage="4 weeks"
/lab_host="DH10B"
/note="Vector: pT73D-Pac (Pharmacia) with a modified
polylinker; Site 1: Not I; Site 2: Eco RI; 1st strand CDNA
was primed with a Not I - oligo(dT) primer [5'
TGTTCACCAATCTGACGTGAGCGCGCCCAATTTTTTTTTTTT 3']
Double-stranded CDNA was ligated to Eco RI adaptors
(Pharmacia), digested with Not I and cloned into the Not
I and Eco RI sites of the modified pT73 vector. RNA
provided by Dr. Minoru Ko, Wayne State Univ. Library
constructed and normalized by Bento Soares and M. Fatima
Bonaldo."

BASE COUNT 4 a 13 c 16 g 8 t

ORIGIN

Query Match 55.6%; Score 10; DB 34; Length 41;
Best Local Similarity 100.0%; Pred. No. 1.2e+05;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGCGTGGCG 10
 |||||
 Db 29 CAGCGTGGCG 20

RESULT 14
 A0025518 45 bp DNA GSS 14-OCT-1998
 LOCUS EP(X)1587 Drosophila melanogaster EP line Drosophila melanogaster
 DEFINITION genomic Sequence recovered from 5' end of P element, genomic survey
 sequence.

ACCESSION A0025518
 VERSION A0025518.1 GI:3265870
 KEYWORDS GSS.
 SOURCE fruit fly.
 ORGANISM Drosophila melanogaster
 Eukaryota; Metazoa; Arthropoda; Tracheata; Hexapoda; Insecta;
 Pterygota; Neoptera; Endopterygota; Diptera; Brachycera;
 Muscomorpha; Ephydroidea; Drosophilidae; Drosophila.
 1 (bases 1 to 45)
 Rehm,E.J. and Rubin,G.M.
 The BDP gene disruption project: single EP element insertions
 unpublished (1998)
 CONTACT: Gerald Rubin
 Berkeley Drosophila Genome Project
 University of California, Berkeley
 USA Building, Berkeley, CA 94720-3200, USA
 Fax: 5106439947
 Email: gerry@fruitfly.berkeley.edu

REFERENCE
 AUTHORS Rehm,E.J. and Rubin,G.M.
 TITLE The BDP gene disruption project: single EP element insertions
 JOURNAL unpublished (1998)
 COMMENT

Sequence recovery method was Inverse PCR.
 Sequence orientation is forward strand relative to 5' end of P
 element

The P element insertion position is base 38 in the 45 bases. This
 insertion position refers to the first base of the 8 base target
 recognition sequence.

FEATURES
 Class: transposon-tagged.
 source location/Qualifiers
 1.45
 /organism="Drosophila melanogaster"
 /db_xref="taxon:7227"
 /clone_lib="Drosophila melanogaster EP line"
 /note="Inverse PCR was performed on Drosophila
 melanogaster strains each of which contains a single EP
 transposable element insertion. (The generation of these
 insertion strains is described in North P, Szabo K, Bailey
 A, Laverly T, Rehm J, Rubin GM, Weidmann K, Millan M, Benes
 V, Ansoerge W, Cohen SM, 1998. Systematic gain-of-function
 genetics in Drosophila. Development 6:1049-1057.) The
 resultant fragment for each strain was directly sequenced
 to determine the genomic sequence at the site of
 insertion. Details of the protocols used can be found at
 http://fruitfly.berkeley.edu/P-disrupt/Inverse_pcr.html."

BASE COUNT 5 a 20 c 9 g 11 t

ORIGIN

Query Match 55.6%; Score 10; DB 94; Length 45;
 Best Local Similarity 72.2%; Pred. No. 1.2e+05;
 Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 1 CAGCGTGGCGCATCCTTC 18
 |||||
 Db 4 CACCTTCGTCATCCTTC 21

RESULT 15
 A1254752 49 bp mRNA EST 02-DEC-1998
 LOCUS A1254752/C
 DEFINITION qt89f07.x1 NCI_CGAP_Col4 Homo sapiens cDNA clone IMAGE:1962469 3'

similar to SW:WASP_MOUSE P70315 WISKOTT-ALDRICH SYNDROME PROTEIN
 HOMOLOG: contains element MSRI repetitive element ;, mRNA sequence.

ACCESSION A1254752
 VERSION A1254752.1 GI:3862277
 KEYWORDS EST.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
 Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE
 AUTHORS NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
 TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
 Tumor Gene Index
 JOURNAL Unpublished (1997)
 COMMENT On Jan 19, 1998 this sequence version replaced gi:2045048.
 Contact: Robert Strausberg, Ph.D.
 Tel: (301) 496-1550
 Email: Robert.Strausberg@nih.gov
 Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R.
 Emmert-Buck, M.D., Ph.D.
 CDNA Library Preparation: Life Technologies, Inc.
 CDNA Library Arrayed by: Greg Lennon, Ph.D.
 DNA Sequencing by: Washington University Genome Sequencing Center
 Clone distribution: NCI-CGAP clone distribution information can be
 found through the I.M.A.G.E. Consortium/RLNT at:
 www.bio.llnl.gov/dbp/image/image.html

Trace considered overall poor quality
 Insert Length: 764 Std Error: 0.00
 Seg primer: -40UP from Gibco
 High quality sequence stop: 1.
 Location/Qualifiers
 1.49
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone_image="1962469"
 /clone_lib="NCI_CGAP_Col4"
 /tissue_type="moderately-differentiated adenocarcinoma"
 /lab_host="DH10B"
 /note="Organ: colon; Vector: pCMV-SPOK6; Site_1: SalI;
 Site_2: NotI; Cloned unidirectionally. Primer: Oligo dT.
 Average insert size 1.7 kb. Life Technologies catalog #:
 11531-019"

BASE COUNT 4 a 19 c 22 g 4 t

ORIGIN

Query Match 55.6%; Score 10; DB 44; Length 49;
 Best Local Similarity 100.0%; Pred. No. 1.2e+05;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 AGCGTGGCGC 11
 |||||
 Db 25 AGCGTGGCGC 16

Search completed: June 18, 2000, 20:38:40
 Job time: 7500 sec

THIS PAGE BLANK (USPTO)

PT of human solid tumours, esp. breast cancer
 PS Example 12; Page 33; 108pp; English.
 CC Antisense oligonucleotides were tested for their ability to induce
 CC programmed cell death (DNA fragmentation) in the human lymphoma cell
 CC line RS11846. The oligonucleotides are phosphodiester targeted
 CC against the translation initiation site (Q86550-55) or the 5'-cap
 CC region (Q86555-58) of human bcl-2 pre-mRNAs. A bcl-2 sense sequence
 CC (Q86649) was used as a control.
 SQ Sequence 20 Bp; 4 A; 4 C; 10 G; 2 T;

Query Match 100.0%; Score 18; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.64;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CAGCGTGGCCCATCCTTC 18
 |||||||
 DB 20 CAGCGTGGCCCATCCTTC 3

RESULT 3
 VI9651
 ID VI9651 standard; DNA: 20 Bp.
 AC VI9651:

DT 12-JUN-1998 (first entry)
 DE Human bcl-2 antisense oligonucleotide 1.
 KM Antisense oligonucleotide; bcl-2 gene; lymphoma; leukaemia; human;
 KW cancer; ss.
 OS Synthetic.
 PN Homo sapiens.
 PD US5734033-A.
 PD 31-MAR-1998.
 PR 24-MAR-1994; 288692.
 PR 21-FEB-1992; US-840716.
 PR 22-DEC-1988; US-288692.
 PR 24-MAR-1994; US-217082.
 PA (UYPE-) UNIV PENNSYLVANIA.
 PI Reed J;
 DR WPI; 98-229881/20.
 PT Anti-sense oligo:nucleotide(s) complementary to BCL-2 mRNA - useful
 PT for treating cancers; e.g. lymphoma(s) and some leukaemia(s)
 PS Claim 6; Columns 3-4; 21pp; English.
 CC This antisense oligonucleotide is complementary to the translation
 CC initiation site of the human bcl-2 mRNA. The Bcl-2 antisense
 CC oligonucleotides are phosphorothioate derivatives and can straddle
 CC strategic sites such as the translation initiation site, donor and
 CC acceptor splicing sites, or sites for transportation or degradation.
 CC Blocking translation at such strategic sites prevents the formation of
 CC a functional bcl-2 gene product. These oligonucleotides may be used for
 CC treating cancers associated with high levels of bcl-2 gene expression,
 CC especially lymphomas and some leukaemias.
 SQ Sequence 20 Bp; 2 A; 10 C; 4 G; 4 T;

Query Match 100.0%; Score 18; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.64;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CAGCGTGGCCCATCCTTC 18
 |||||||
 DB 1 CAGCGTGGCCCATCCTTC 18

RESULT 4
 VI9657/C
 ID VI9657 standard; DNA: 20 Bp.
 AC VI9657:

DT 12-JUN-1998 (first entry)
 DE Human bcl-2 transcription initiation sense (TI-S) oligonucleotide.
 KW Antisense oligonucleotide; bcl-2 gene; lymphoma; leukaemia; human;
 OS cancer; ss.
 OS Synthetic.
 OS Homo sapiens.

PN US5734033-A.
 PD 31-MAR-1998.
 PD 24-MAR-1994; 288692.
 PR 21-FEB-1992; US-840716.
 PR 22-DEC-1988; US-288692.
 PR 24-MAR-1994; US-217082.
 PA (UYPE-) UNIV PENNSYLVANIA.
 PI Reed J;
 DR WPI; 98-229881/20.
 PT Anti-sense oligo:nucleotide(s) complementary to BCL-2 mRNA - useful
 PT for treating cancers; e.g. lymphoma(s) and some leukaemia(s)
 PS Disclosure; Column 19; 21pp; English.
 CC This oligonucleotide is used as a control in measuring DNA fragmentation
 CC as an indicator of bcl-2 antisense oligonucleotide mediated programmed
 CC cell death in human lymphoma cells. Bcl-2 antisense oligonucleotides
 CC straddle strategic sites such as the translation initiation site, donor
 CC and acceptor splicing sites, or sites for transportation or degradation.
 CC Blocking translation at such strategic sites prevents the formation of a
 CC functional bcl-2 gene product. These oligonucleotides may be used for
 CC treating cancers associated with high levels of bcl-2 gene expression,
 CC especially lymphomas and some leukaemias.
 SQ Sequence 20 Bp; 4 A; 4 C; 10 G; 2 T;

Query Match 100.0%; Score 18; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.64;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CAGCGTGGCCCATCCTTC 18
 |||||||
 DB 20 CAGCGTGGCCCATCCTTC 3

RESULT 5
 Q49816
 ID Q49816 standard; DNA: 22 Bp.
 AC Q49816:

DT 03-MAY-1994 (first entry)
 DE Bcl-2 antisense oligonucleotide.
 KM Cell death; apoptosis; inhibition; de-inhibition; bcl-2 oncogene;
 KW expression; myc; ss.
 OS Synthetic.
 PN WO9320200-A.
 PD 14-OCT-1993.
 PD 02-APR-1993; G00686.
 PR 02-APR-1992; GB-007275.
 PR 02-APR-1992; GB-007276.
 PA (IMCR) IMPERIAL CANCER RES TECHNOLOGY.
 PI Evan GI;
 DR WPI; 93-336908/42.
 PT Treating tumour cells by de-inhibiting Myc-induced apoptosis -
 PT esp. by inhibiting expression of the BCL-2 oncogene e.g. with
 PT cultured cells by expressing BCL-2
 PT antisense oligo:nucleotide(s), also increasing survival of
 PS Disclosure; Page 58; 109pp; English.
 CC A DNA construct comprising the bcl-2 coding sequence under control
 CC of elements allowing its expression is claimed. Myc-induced cell
 CC death can be inhibited in cultured cells by expressing bcl-2.
 CC Myc-induced cell death can be de-inhibited in tumour cells by admin.
 CC of bcl-2 antisense oligonucleotides.
 SQ Sequence 22 Bp; 2 A; 12 C; 4 G; 4 T;

Query Match 100.0%; Score 18; DB 1; Length 22;
 Best Local Similarity 100.0%; Pred. No. 0.64;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CAGCGTGGCCCATCCTTC 18
 |||||||
 DB 3 CAGCGTGGCCCATCCTTC 20

RESULT 6

049817
 ID 049817 standard; RNA; 22 BP.
 AC 049817;
 DT 03-MAY-1994 (first entry)
 DE Bcl-2 antisense oligonucleotide.
 KW Cell death; apoptosis; inhibition; de-inhibition; bcl-2 oncogene;
 OS expression; myc; ss.
 PN Synthetic.
 PD WO9320200-A.
 PF 14-OCT-1993.
 PR 02-APR-1993; G00686.
 PR 02-APR-1992; GB-007275.
 PR 02-APR-1992; GB-007276.
 PA (IMCR) IMPERIAL CANCER RES TECHNOLOGY.
 PI Evan GJ.
 DR WPI: 93-336908/42.
 PT Treating tumour cells by de-inhibiting Myc-induced apoptosis -
 PT esp. by inhibiting expression of the BCL-2 oncogene e.g. with
 PT antisense oligo:nucleotide(s), also increasing survival of
 PT cultured cells by expressing BCL-2
 PS Disclosure: Page 58; 109pp; English.
 CC A DNA construct comprising the bcl-2 coding sequence under control
 CC of elements allowing its expression is claimed. Myc-induced cell
 CC death can be inhibited in cultured cells by expressing bcl-2.
 CC Myc-induced cell death can be de-inhibited in tumour cells by admin.
 CC of bcl-2 antisense oligonucleotides.
 SQ Sequence 22 BP: 2 A; 12 C; 4 G; 4 U;

Query Match 100.0%; Score 18; DB 1; Length 22;
 Best Local Similarity 77.8%; Pred. No. 0.64;
 Matches 14; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1 CACGTCGCCATCCTTC 18
 |||||:|||||:|:|:
 DB 3 CACGTCGCCATCCTTC 20

RESULT 7
 086644/c
 ID 086644 standard; DNA; 35 BP.
 AC 086644;
 DT 27-SEP-1995 (first entry)
 DE Bcl-2 translation initiation region.
 KW Anticodon oligomer; antisense oligonucleotide; bcl-2; cancer; therapy;
 KW leukemia; lymphoma; solid tumor; breast cancer; autoimmune disease;
 KW ss.
 OS Synthetic.
 PN WO9508350-A.
 PD 30-MAR-1995.
 PF 20-SEP-1994; U10725.
 PR 20-SEP-1993; US-124256.
 PA (REED/J) REED J C.
 PI Reed JC.
 DR WPI: 95-139394/18.
 PT Anti-code oligomers which bind to bcl-2 mRNA - for the treatment
 PT of human solid tumours, esp. breast cancer
 PS Disclosure: Page 13; 108pp; English.
 CC The antisense oligonucleotide Tr-AS (086643) straddles the
 CC translation-initiation site in the mRNA coding strand of the human
 CC bcl-2 gene and is complementary to this region. It reduces the
 CC expression of bcl-2 gene product thereby inducing programmed cell
 CC death of certain cancer cells. The corresp. sense bcl-1 sequence
 CC was synthesized for use as a control.
 SQ Sequence 35 BP: 6 A; 8 C; 13 G; 8 T;

Query Match 100.0%; Score 18; DB 1; Length 35;
 Best Local Similarity 100.0%; Pred. No. 0.66;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CACGTCGCCATCCTTC 18
 |||||:|||||:|:|:

DB 30 CACGTCGCCATCCTTC 13
 RESULT 8
 ID V19652/c
 V19652 standard; DNA; 35 BP.
 AC V19652;
 DT 12-JUN-1998 (first entry)
 DE Human bcl-2 oligonucleotide 1.
 KW Antisense oligonucleotide; bcl-2 gene; lymphoma; leukaemia; human;
 KW cancer; ss.
 OS Synthetic.
 PN Homo sapiens.
 PD US5734033-A.
 PF 31-MAR-1998.
 PR 24-MAR-1994; 288692.
 PR 21-FEB-1992; US-840716.
 PR 22-DEC-1988; US-288692.
 PR 24-MAR-1994; US-217082.
 PA (UYPE-) UNIV PENNSYLVANIA.
 PI Reed J.
 DR WPI: 98-229881/20.
 PT Anti-sense oligo:nucleotide(s) complementary to BCL-2 mRNA - useful
 PT for treating cancers, e.g. lymphoma(s) and some leukaemia(s)
 PS Claim 1: Columns 3-4; 21pp; English.
 CC This is a human bcl-2 oligonucleotide based on which an antisense
 CC oligonucleotide complementary to the translation initiation site of the
 CC human bcl-2 mRNA can be constructed. Bcl-2 antisense oligonucleotides
 CC straddle strategic sites such as the translation initiation site, donor
 CC and acceptor splicing sites, or sites for transportation or degradation.
 CC Blocking translation at such strategic sites prevents the formation of a
 CC functional bcl-2 gene product. These oligonucleotides may be used for
 CC treating cancers associated with high levels of bcl-2 gene expression,
 CC especially lymphomas and some leukaemias.
 SQ Sequence 35 BP: 6 A; 8 C; 13 G; 8 T;

Query Match 100.0%; Score 18; DB 1; Length 35;
 Best Local Similarity 100.0%; Pred. No. 0.66;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CACGTCGCCATCCTTC 18
 |||||:|||||:|:|:
 DB 30 CACGTCGCCATCCTTC 13

RESULT 9
 V19660
 ID V19660 standard; DNA; 17 BP.
 AC V19660;
 DT 12-JUN-1998 (first entry)
 DE Human bcl-2 antisense oligonucleotide 6.
 KW Antisense oligonucleotide; bcl-2 gene; lymphoma; leukaemia; human;
 KW cancer; ss.
 OS Synthetic.
 PN Homo sapiens.
 PD US5734033-A.
 PF 31-MAR-1998.
 PR 24-MAR-1994; 288692.
 PR 21-FEB-1992; US-840716.
 PR 22-DEC-1988; US-288692.
 PR 24-MAR-1994; US-217082.
 PA (UYPE-) UNIV PENNSYLVANIA.
 PI Reed J.
 DR WPI: 98-229881/20.
 PT Anti-sense oligo:nucleotide(s) complementary to BCL-2 mRNA - useful
 PT for treating cancers, e.g. lymphoma(s) and some leukaemia(s)
 PS Claim 6: Column 14; 21pp; English.
 CC This antisense oligonucleotide is complementary to the translation
 CC initiation site of the human bcl-2 mRNA. The Bcl-2 antisense
 CC oligonucleotides are phosphorothioate derivatives and can straddle
 CC strategic sites such as the translation initiation site, donor and
 CC acceptor splicing sites, or sites for transportation or degradation.

CC Blocking translation at such strategic sites prevents the formation of
 CC a functional bcl-2 gene product. These oligonucleotides may be used for
 CC treating cancers associated with high levels of bcl-2 gene expression,
 CC especially lymphomas and some leukaemias.
 SQ Sequence 17 Bp; 2 A; 8 C; 4 G; 3 T;

Query Match 88.9%; Score 16; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 6.9;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CAGCGTGGCCATCCT 16
 |||
 DB 2 CAGCGTGGCCATCCT 17

RESULT 10

VI9661
 ID VI9661 standard; DNA; 17 Bp.

AC VI9661;
 DT 12-JUN-1998 (first entry)
 DE Human bcl-2 antisense oligonucleotide 7.
 KW Antisense oligonucleotide; bcl-2 gene; lymphoma; leukaemia; human;
 KM cancer; ss.
 OS Synthetic.
 OS Homo sapiens.
 PN US5734033-A.
 PD 31-MAR-1998.
 PF 24-MAR-1994; 288692.
 PR 21-FEB-1992; US-840716.
 PR 22-DEC-1988; US-288692.
 PR 24-MAR-1994; US-217082.
 PA (UYPE-) UNIV PENNSYLVANIA.
 PI Reed J;
 DR WPI; 98-229881/20.
 PT Anti-sense oligo:nucleotide(s) complementary to BCL-2 mRNA - useful
 for treating cancers, e.g. lymphoma(s) and some leukaemia(s)
 PS Disclosure; Column 14; 21pp; English.
 CC This antisense oligonucleotide is complementary to the translation
 CC initiation site of the human bcl-2 mRNA. The Bcl-2 antisense
 CC oligonucleotides are phosphorothioate derivatives and can straddle
 CC strategic sites such as the translation initiation site, donor and
 CC acceptor splicing sites, or sites for transportation or degradation.
 CC Blocking translation at such strategic sites prevents the formation of
 CC a functional bcl-2 gene product. These oligonucleotides may be used for
 CC treating cancers associated with high levels of bcl-2 gene expression,
 CC especially lymphomas and some leukaemias.
 SQ Sequence 17 Bp; 1 A; 8 C; 4 G; 4 T;

Query Match 88.9%; Score 16; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 6.9;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 3 GCGTGGCCATCCTTC 18
 |||
 DB 1 GCGTGGCCATCCTTC 16

RESULT 11

VI9662
 ID VI9662 standard; DNA; 17 Bp.

AC VI9662;
 DT 12-JUN-1998 (first entry)
 DE Human bcl-2 antisense oligonucleotide 8.
 KW Antisense oligonucleotide; bcl-2 gene; lymphoma; leukaemia; human;
 KM cancer; ss.
 OS Synthetic.
 OS Homo sapiens.
 PN US5734033-A.
 PD 31-MAR-1998.
 PF 24-MAR-1994; 288692.
 PR 21-FEB-1992; US-840716.

PR 22-DEC-1988; US-288692.
 PR 24-MAR-1994; US-217082.
 PA (UYPE-) UNIV PENNSYLVANIA.
 PI Reed J;
 DR WPI; 98-229881/20.

PT Anti-sense oligo:nucleotide(s) complementary to BCL-2 mRNA - useful
 for treating cancers, e.g. lymphoma(s) and some leukaemia(s)
 PS Disclosure; Column 14; 21pp; English.
 CC This antisense oligonucleotide is complementary to the translation
 CC initiation site of the human bcl-2 mRNA. The Bcl-2 antisense
 CC oligonucleotides are phosphorothioate derivatives and can straddle
 CC strategic sites such as the translation initiation site, donor and
 CC acceptor splicing sites, or sites for transportation or degradation.
 CC Blocking translation at such strategic sites prevents the formation of
 CC a functional bcl-2 gene product. These oligonucleotides may be used for
 CC treating cancers associated with high levels of bcl-2 gene expression,
 CC especially lymphomas and some leukaemias.
 SQ Sequence 17 Bp; 2 A; 8 C; 3 G; 4 T;

Query Match 72.2%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.5e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 6 TCGCCATCCTTC 18
 |||
 DB 1 TCGCCATCCTTC 13

RESULT 12

VI9659
 ID VI9659 standard; DNA; 17 Bp.

AC VI9659;
 DT 12-JUN-1998 (first entry)
 DE Human bcl-2 antisense oligonucleotide 5.
 KW Antisense oligonucleotide; bcl-2 gene; lymphoma; leukaemia; human;
 KM cancer; ss.
 OS Synthetic.
 OS Homo sapiens.
 PN US5734033-A.
 PD 31-MAR-1998.
 PF 24-MAR-1994; 288692.
 PR 21-FEB-1992; US-840716.
 PR 22-DEC-1988; US-288692.
 PR 24-MAR-1994; US-217082.
 PA (UYPE-) UNIV PENNSYLVANIA.
 PI Reed J;
 DR WPI; 98-229881/20.

PT Anti-sense oligo:nucleotide(s) complementary to BCL-2 mRNA - useful
 for treating cancers, e.g. lymphoma(s) and some leukaemia(s)
 PS Claim 6; Column 14; 21pp; English.
 CC This antisense oligonucleotide is complementary to the translation
 CC initiation site of the human bcl-2 mRNA. The Bcl-2 antisense
 CC oligonucleotides are phosphorothioate derivatives and can straddle
 CC strategic sites such as the translation initiation site, donor and
 CC acceptor splicing sites, or sites for transportation or degradation.
 CC Blocking translation at such strategic sites prevents the formation of
 CC a functional bcl-2 gene product. These oligonucleotides may be used for
 CC treating cancers associated with high levels of bcl-2 gene expression,
 CC especially lymphomas and some leukaemias.
 SQ Sequence 17 Bp; 2 A; 8 C; 4 G; 3 T;

Query Match 72.2%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.5e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CAGCGTGGCCAT 13
 |||
 DB 5 CAGCGTGGCCAT 17

RESULT 13

08659

ID 08659 standard; DNA; 18 BP.

AC 08659: standard; DNA; 18 BP.

DE 27-SEP-1995 (first entry)

DE bcl-2 antisense oligonucleotide.

KW Anticodon oligomer; antisense oligonucleotide; bcl-2; cancer; therapy;

KW Chemoresistance; ss.

OS Synthetic.

FH Key

FT misc_feature

FT 1..18

FT /tag= a

FT /note= "3'-5' (antisense) sequence"

FT W0908350-A.

PD 30-MAR-1995.

PD 20-SEP-1994; U10725.

PR 20-SEP-1993; US-124256.

PA (REED/J) REED J C.

PI Reed JC;

DR MPI; 95-139394/18.

PT Anti-code oligomers which bind to bcl-2 mRNA - for the treatment

PT of human solid tumours, esp. breast cancer

PS Example 18; Page 44; 108pp; English.

CC Reversal of chemoresistance of tumor cells by antisense-mediated

CC reduction of bcl-2 expression was demonstrated using the

CC oligonucleotide given in 08659. This is antisense to the first

CC 6 codons of the bcl-2 ORF.

SQ Sequence 18 BP; 2 A; 8 C; 4 G; 4 T;

Query Match

Best Local Similarity 100.0%; Score 13; DB 1; Length 18; Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CAGCGTGGCCCAT 13

Db 6 CAGCGTGGCCCAT 18

RESULT 14

V19667

ID V19667 standard; DNA; 18 BP.

AC V19667: standard; DNA; 18 BP.

DE 12-JUN-1998 (first entry)

DE Human bcl-2 antisense oligonucleotide 13.

KW Antisense oligonucleotide; bcl-2 gene; lymphoma; leukaemia; human;

KW cancer; ss.

OS Synthetic.

PS Homo sapiens.

PN US5734033-A.

PD 31-MAR-1998.

PD 24-MAR-1994; 288692.

PR 21-FEB-1992; US-840716.

PR 22-DEC-1988; US-288692.

PR 24-MAR-1994; US-217082.

PA (UYBE-) UNIV PENNSYLVANIA.

PI Reed J.

DR MPI; 96-229881/20.

PT Anti-sense oligo:nucleotide(s) complementary to BCL-2 mRNA - useful

PT for treating cancers, e.g. lymphoma(s) and some leukaemia(s)

PS Disclosure: Column 23; 21pp; English.

CC This antisense oligonucleotide is complementary to the translation

CC initiation site of the human bcl-2 mRNA. The Bcl-2 antisense

CC oligonucleotides are phosphorothioate derivatives and can straddle

CC strategic sites such as the translation initiation site, donor and

CC acceptor splicing sites, or sites for transportation or degradation.

CC Blocking translation at such strategic sites prevents the formation of

CC a functional bcl-2 gene product. These oligonucleotides may be used for

CC treating cancers associated with high levels of bcl-2 gene expression,

CC especially lymphomas and some leukaemias.

SQ Sequence 18 BP; 2 A; 8 C; 4 G; 4 T;

Query Match

Best Local Similarity 100.0%; Score 13; DB 1; Length 18; Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Best Local Similarity 100.0%; Pred. No. 2.5e+02; Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CAGCGTGGCCCAT 13

Db 6 CAGCGTGGCCCAT 18

RESULT 15

V27719

ID V27719 standard; DNA; 18 BP.

AC V27719: standard; DNA; 18 BP.

DE 01-OCT-1998 (first entry)

DE Immunostimulatory oligodeoxynucleotide of the invention.

KW Immunostimulatory; oligodeoxynucleotide; ODN;

KW unmethylated CpG dinucleotide; activate; lymphocyte; immune response;

KW Th2; Th1; cytokine; treatment; prevention; asthma; autoimmune disease;

KW desensitisation therapy; artificial adjuvant; antibody generation; ss.

OS Synthetic.

PN W0918810-A1.

PD 07-MAY-1998.

PR 30-OCT-1997; U19791.

PR 30-OCT-1996; US-738652.

PA (IOWA) UNIV IOWA RES FOUNDD.

PI Kline JN, Krieg AM;

DR MPI; 98-272127/24.

PT New immunostimulatory nucleic acid molecules - which contain at

PT least one unmethylated CpG dinucleotide, used for treating e.g.

PT tumours, infections or autoimmune disease

PS Disclosure: Page 49; 109pp; English.

CC V27641-751 represent immunostimulatory oligodeoxynucleotides (ODNs)

CC of the invention. The ODNs contain at least one unmethylated CpG

CC dinucleotide, and have the formula:

CC 5' N1X1GxN2 3', where at least one nucleotide separates consecutive

CC CpGs, X1 is adenine, guanine, or thymine, X2 is cytosine or thymine, N1

CC any nucleotide and N1+N2 is 0-26 bases with the provision that N1 and N2

CC does not contain a CCG tetramer or more than one CCG or CCG trimer OR

CC 5' NX12CGx3X4N 3', where at least one nucleotide separates consecutive

CC CpGs, X1 and X2 are selected from GpT, GpG, GpA, APT and APA, X3 and X4

CC are selected from Tpt or Cpt, N1 is any nucleotide and N1+N2 is 0-26

CC bases with the provision that N1 and N2 does not contain a CCG tetramer

CC or more than one CCG or CCG trimer.

CC The ODNs activate lymphocytes in a subject and redirect a subject's

CC immune response from a Th2 (e.g. by inducing monocytic cells and

CC other cells to produce Th1 cytokines, including IL-12, IFN-gamma and

CC GM-CSF). The ODNs can be used to treat or prevent an asthmatic disorder,

CC autoimmune diseases, in desensitisation therapy, as an artificial

CC adjuvant during antibody generation in a mammal such as a mouse or a

CC human.

SQ Sequence 18 BP; 2 A; 8 C; 4 G; 4 T;

Query Match

Best Local Similarity 100.0%; Score 13; DB 1; Length 18; Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CAGCGTGGCCCAT 13

Db 6 CAGCGTGGCCCAT 18

Search completed: June 18, 2000, 20:48:51
Job time: 5324 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 18, 2000, 18:48:20 ; Search time 491.24 Seconds
(without alignments)
-35.645 Million cell updates/sec

Title: PCT-US97-18348-1
Perfect score: 18
Sequence: 1 CAGCGTGGCCATCCTTC 18

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 1.0

Searched: 882769 seqs, -486395729 residues

Total number of hits satisfying chosen parameters: 285916

Minimum DB seq length: 0
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Listing first 45 summaries

Database :

GenEmbl:*
1: gb_ba1:*
2: gb_ba2:*
3: gb_cm:*
4: gb_ov:*
5: gb_pac:*
6: gb_ph:*
7: gb_pl1:*
8: gb_pl2:*
9: gb_pl3:*
10: gb_pr2:*
11: gb_pr3:*
12: gb_ro:*
13: gb_sts:*
14: gb_sy:*
15: gb_un:*
16: gb_vl:*
17: em_fun:*
18: em_hum1:*
19: em_hum2:*
20: em_hum3:*
21: em_hum4:*
22: em_hum5:*
23: em_hum6:*
24: em_hum7:*
25: em_hum8:*
26: em_hum9:*
27: em_hum10:*
28: em_hum11:*
29: em_hum12:*
30: em_hum13:*
31: em_hum14:*
32: em_hum15:*
33: em_hum16:*
34: em_hum17:*
35: em_hum18:*
36: em_hum19:*
37: em_hum20:*
38: em_hum21:*
39: em_hum22:*
40: em_hum23:*
41: em_hum24:*
42: em_hum25:*
43: em_hum26:*
44: em_hum27:*

45: gb_hcg7:*
46: em_hcg1:*
47: em_hcg2:*
48: em_hcg3:*
49: em_hcg4:*
50: em_hcg5:*
51: gb_pr5:*
52: gb_hcg8:*
53: gb_hcg9:*
54: gb_hcg10:*
55: gb_hcg11:*
56: gb_hcg12:*
57: gb_hcg13:*
58: gb_hcg14:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	18	100.0	20	5 AR052603	AR052603 Sequence
2	18	100.0	20	5 AR052609	AR052609 Sequence
3	18	100.0	20	5 I96082	I96082 Sequence 1
4	18	100.0	20	5 I96088	I96088 Sequence 7
5	18	100.0	22	5 A76123	A76123 Sequence 3
6	18	100.0	22	5 A76124	A76124 Sequence 4
7	18	100.0	35	5 AR052604	AR052604 Sequence 2
8	18	100.0	35	5 I96083	I96083 Sequence 10
9	16	88.9	17	5 I96091	I96091 Sequence 10
10	16	88.9	17	5 I96092	I96092 Sequence 11
11	14	77.8	29	4 CHRC2A101	K02260 Chicken alp
12	13	72.2	17	5 I96090	I96090 Sequence 9
13	13	72.2	17	5 I96093	I96093 Sequence 12
14	13	72.2	18	5 AR052619	AR052619 Sequence
15	13	72.2	18	5 AR052624	AR052624 Sequence
16	13	72.2	18	5 I96098	I96098 Sequence 17
17	13	72.2	27	5 AR004426	AR004426 Sequence
18	13	72.2	27	5 I43661	I43661 Sequence 13
19	13	72.2	27	5 I86720	I86720 Sequence 8
20	13	72.2	25	5 I09491	I09491 Sequence 5
21	11.8	65.6	45	5 I12347	I12347 Sequence 36
22	11.8	65.6	45	5 I70250	I70250 Sequence 36
23	11.8	65.6	48	5 AR021008	AR021008 Sequence
24	11.8	65.6	48	5 AR043423	AR043423 Sequence
25	11.8	65.6	48	5 AR062338	AR062338 Sequence
26	11.8	61.1	31	5 AR041195	AR041195 Sequence
27	10.8	60.0	17	5 I46922	I46922 Sequence 15
28	10.8	60.0	21	5 A98631	A98631 Sequence 25
29	10.8	60.0	26	24 E11773	E11773 Synthetic
30	10.8	60.0	35	5 I15202	I15202 Sequence 19
31	10.8	60.0	35	5 I15205	I15205 Sequence 22
32	10.8	60.0	36	5 A26295	A26295 Subtilisin
33	10.8	60.0	36	5 A26296	A26296 Subtilisin
34	10.8	60.0	36	5 A26927	A26927 Oligonucleo
35	10.8	60.0	36	5 A26928	A26928 Oligonucleo
36	10.8	60.0	36	5 I43384	I43384 Sequence 13
37	10.8	60.0	36	5 I43385	I43385 Sequence 14
38	10.6	58.9	20	5 A51364	A51364 Sequence 6
39	10.6	58.9	20	5 AR066873	AR066873 Sequence
40	10.6	58.9	12	12 XMHNFI13B	X65552 Mus musculu
41	10.6	58.9	33	5 AR008552	AR008552 Sequence
42	10.6	58.9	38	5 AR029330	AR029330 Sequence
43	10.6	58.9	42	5 AR008961	AR008961 Sequence
44	10.6	58.9	42	5 I24415	I24415 Sequence 10
45	10.6	58.9	50	5 A25419	A25419 Oligonucleo

ALIGNMENTS

RESULT 1
AR052603 AR052603 20 bp DNA PAT 29-SEP-1998
LOCUS Sequence 1 from patent US 5831066.
DEFINITION
ACCESSION AR052603
VERSION AR052603.1 GI:5975967
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Reed,J.C.
TITLE Regulation of bcl-2 gene expression
JOURNAL Patent: US 5831066-A 1 03-NOV-1998;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
BASE COUNT 2 a 10 c 4 g 4 t
ORIGIN

Query Match 100.0%; Score 18; DB 5; Length 20;
Best Local Similarity 100.0%; Pred. No. 41;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGCGTGGCCCATCCTTC 18
|||||
Db 1 CAGCGTGGCCCATCCTTC 18

RESULT 2
AR052609/c AR052609 20 bp DNA PAT 29-SEP-1998
LOCUS Sequence 7 from patent US 5831066.
DEFINITION
ACCESSION AR052609
VERSION AR052609.1 GI:5975973
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Reed,J.C.
TITLE Regulation of bcl-2 gene expression
JOURNAL Patent: US 5831066-A 7 03-NOV-1998;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
BASE COUNT 4 a 4 c 10 g 2 t
ORIGIN

Query Match 100.0%; Score 18; DB 5; Length 20;
Best Local Similarity 100.0%; Pred. No. 41;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGCGTGGCCCATCCTTC 18
|||||
Db 20 CAGCGTGGCCCATCCTTC 3

RESULT 3
196082 20 bp DNA PAT 01-DEC-1998
LOCUS Sequence 1 from patent US 5734033.
DEFINITION
ACCESSION 196082
VERSION 196082.1 GI:3940552
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Reed,J.

TITLE Antisense oligonucleotides inhibiting human bcl-2 gene expression
JOURNAL Patent: US 5734033-A 1 31-MAR-1998;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
BASE COUNT 2 a 10 c 4 g 4 t
ORIGIN

Query Match 100.0%; Score 18; DB 5; Length 20;
Best Local Similarity 100.0%; Pred. No. 41;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGCGTGGCCCATCCTTC 18
|||||
Db 1 CAGCGTGGCCCATCCTTC 18

RESULT 4
196088 20 bp DNA PAT 01-DEC-1998
LOCUS Sequence 7 from patent US 5734033.
DEFINITION
ACCESSION 196088
VERSION 196088.1 GI:3940558
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Reed,J.
TITLE Antisense oligonucleotides inhibiting human bcl-2 gene expression
JOURNAL Patent: US 5734033-A 7 31-MAR-1998;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
BASE COUNT 4 a 4 c 10 g 2 t
ORIGIN

Query Match 100.0%; Score 18; DB 5; Length 20;
Best Local Similarity 100.0%; Pred. No. 41;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGCGTGGCCCATCCTTC 18
|||||
Db 20 CAGCGTGGCCCATCCTTC 3

RESULT 5
A76123 22 bp DNA PAT 19-OCT-1999
LOCUS Sequence 3 from Patent WO9320200.
DEFINITION
ACCESSION A76123
VERSION A76123.1 GI:6088259
KEYWORDS
SOURCE unidentified.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 22)
AUTHORS Evan,G.I.
TITLE MODIFIED CELLS AND METHOD OF TREATMENT
JOURNAL Patent: WO 9320200-A 14-OCT-1993;
IMP CANCER RES TECH (GB); EVAN GERARD IAN (GB)
FEATURES Location/Qualifiers
source 1..22
/organism="unidentified"
/db_xref="taxon:32644"
BASE COUNT 2 a 12 c 4 g 4 t
ORIGIN

Query Match 100.0%; Score 18; DB 5; Length 22;
Best Local Similarity 100.0%; Pred. No. 41;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CACGTCGCCCATCTTC 18
|||||

Db 3 CACGTCGCCCATCTTC 20

RESULT 6
A76124 22 bp DNA PAT 19-OCT-1999
LOCUS
DEFINITION Sequence 4 from Patent WO9320200.
ACCESSION A76124
VERSION A76124.1 GI:6088260
KEYWORDS
SOURCE unidentified.
ORGANISM unidentified.
REFERENCE 1 (bases 1 to 22)
AUTHORS Evan,G.I.
TITLE MODIFIED CELLS AND METHOD OF TREATMENT
JOURNAL Patent: WO 9320200-A 14-OCT-1993;
IMP CANCER RES TECH (GB); EVAN GERARD IAN (GB)
FEATURES
source 1.22
/organism="unidentified"
/db_xref="taxon:33264"

BASE COUNT 2 a 12 c 4 g 4 t

ORIGIN

Query Match 100.0%; Score 18; DB 5; Length 22;
Best Local Similarity 100.0%; Pred. No. 41;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CACGTCGCCCATCTTC 18
|||||

Db 3 CACGTCGCCCATCTTC 20

RESULT 7
AR052604 35 bp DNA PAT 29-SEP-1999
LOCUS AR052604
DEFINITION Sequence 2 from patent US 5831066.
ACCESSION AR052604
VERSION AR052604.1 GI:5975968
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 35)
TITLE Reed,J.C.
JOURNAL Regulation of bcl-2 gene expression
FEATURES Patent: US 5831066-A 2 03-NOV-1998;
source 1.35
Location/Qualifiers
/organism="unknown"

BASE COUNT 6 a 8 c 13 g 8 t

ORIGIN

Query Match 100.0%; Score 18; DB 5; Length 35;
Best Local Similarity 100.0%; Pred. No. 40;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CACGTCGCCCATCTTC 18
|||||

Db 30 CACGTCGCCCATCTTC 13

RESULT 8
196083 35 bp DNA PAT 01-DEC-1998
LOCUS 196083/c
DEFINITION Sequence 2 from patent US 5734033.

ACCESSION 196083
VERSION 196083.1 GI:3940553
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 35)
TITLE Reed,J.
JOURNAL Antisense oligonucleotides inhibiting human bcl-2 gene expression
FEATURES Patent: US 5734033-A 2 31-MAR-1998;
source 1.35
Location/Qualifiers
/organism="unknown"

BASE COUNT 6 a 8 c 13 g 8 t

ORIGIN

Query Match 100.0%; Score 18; DB 5; Length 35;
Best Local Similarity 100.0%; Pred. No. 40;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CACGTCGCCCATCTTC 18
|||||

Db 30 CACGTCGCCCATCTTC 13

RESULT 9
196091 17 bp DNA PAT 01-DEC-1998
LOCUS 196091
DEFINITION Sequence 10 from patent US 5734033.
ACCESSION 196091
VERSION 196091.1 GI:3940561
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 17)
TITLE Reed,J.
JOURNAL Antisense oligonucleotides inhibiting human bcl-2 gene expression
FEATURES Patent: US 5734033-A 10 31-MAR-1998;
source 1.17
Location/Qualifiers
/organism="unknown"

BASE COUNT 2 a 8 c 4 g 3 t

ORIGIN

Query Match 88.9%; Score 16; DB 5; Length 17;
Best Local Similarity 100.0%; Pred. No. 44+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CACGTCGCCCATCTTC 16
|||||

Db 2 CACGTCGCCCATCTTC 17

RESULT 10
196092 17 bp DNA PAT 01-DEC-1998
LOCUS 196092
DEFINITION Sequence 11 from patent US 5734033.
ACCESSION 196092
VERSION 196092.1 GI:3940562
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 17)
TITLE Reed,J.
JOURNAL Antisense oligonucleotides inhibiting human bcl-2 gene expression
FEATURES Patent: US 5734033-A 11 31-MAR-1998;
source 1.17
Location/Qualifiers
/organism="unknown"

BASE COUNT 1 a 8 c 4 g 4 t
ORIGIN

Query Match 88.9%; Score 16; DB 5; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 3 GCGTGGCCATCCTT 18
11111111111111111111
Db 1 GCGTGGCCATCCTT 16

RESULT 11
LOCUS CHKC2A101 29 bp DNA VRT 23-MAY-1996
DEFINITION Chicken alpha-1 type-II collagen gene; amino acids 578 to 585.

ACCESSION K02260
VERSION K02260.1 GI:211336
KEYWORDS alpha-1 type II collagen; collagen.
SEGMENT 1 of 6
SOURCE Gallus gallus (clone: LgCOL(II).) DNA.
ORGANISM Gallus gallus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Archosauria;
Aves; Neognathae; Galliformes; Phasianidae; Phasianinae; Gallus.

REFERENCE 1 (bases 1 to 29)
AUTHORS Sandell, L.J., Yamada, Y., Dorfman, A. and Upholt, W.B.
TITLE Identification of genomic DNA coding for chicken type II procollagen

JOURNAL U. Biol. Chem. 258 (19), 11617-11621 (1983)
MEDLINE 84008159
COMMENT

Each procollagen gene codes for the six successive functional regions of the protein: signal peptide, NH-2 propeptide, NH-2 telopeptide, helical peptide, COOH telopeptide, and COOH propeptide. The type-II COOH-propeptide is cleaved from the procollagen molecule after the triple helical molecule is secreted into the extracellular matrix.

FEATURES
source
1..29
/organism="Gallus gallus"
/db_xref="taxon:9031"
/clone="LgCOL(II)."
/cell_type="reticulocyte"
1..24
/note="preprocollagen alpha-1 type-II, AA 578 to 585"
25..>29
/note="collagen intron"
7 a 7 c 11 g 4 t
BASE COUNT
ORIGIN Downstream of EcoRI site.

exon
intron
BASE COUNT 7 a 7 c 11 g 4 t
ORIGIN Downstream of EcoRI site.

Query Match 77.8%; Score 14; DB 4; Length 29;
Best Local Similarity 100.0%; Pred. No. 4.6e+03;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 4 CGTGCCCATCCTT 17
11111111111111111111
Db 23 CGTGCCCATCCTT 10

RESULT 12
LOCUS 196090 17 bp DNA PAT 01-DEC-1998
DEFINITION Sequence 9 from patent US 5734033.
ACCESSION 196090
VERSION 196090.1 GI:3940560
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 17)
TITLE Antisense oligonucleotides inhibiting human bcl-2 gene expression

JOURNAL Patent: US 5734033-A 9 31-MAR-1998;
FEATURES
source
1..17
/organism="unknown"
BASE COUNT 2 a 8 c 4 g 3 t
ORIGIN

Query Match 72.2%; Score 13; DB 5; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CAGCGTGGCCCAT 13
11111111111111111111
Db 5 CAGCGTGGCCCAT 17

RESULT 13
LOCUS 196093 17 bp DNA PAT 01-DEC-1998
DEFINITION Sequence 12 from patent US 5734033.
ACCESSION 196093
VERSION 196093.1 GI:3940563
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 17)
TITLE Antisense oligonucleotides inhibiting human bcl-2 gene expression

JOURNAL Patent: US 5734033-A 12 31-MAR-1998;
FEATURES
source
1..17
/organism="unknown"
BASE COUNT 2 a 8 c 3 g 4 t
ORIGIN

Query Match 72.2%; Score 13; DB 5; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 6 TGGCGCATCCTT 18
11111111111111111111
Db 1 TGGCGCATCCTT 13

RESULT 14
LOCUS AR052619 18 bp DNA PAT 29-SEP-1999
DEFINITION Sequence 17 from patent US 5831066.
ACCESSION AR052619
VERSION AR052619.1 GI:5975983
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 18)
TITLE Regulation of bcl-2 gene expression

JOURNAL Patent: US 5831066-A 17 03-NOV-1998;
FEATURES
source
1..18
/organism="unknown"
BASE COUNT 2 a 8 c 4 g 4 t
ORIGIN

Query Match 72.2%; Score 13; DB 5; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CAGCGTGGCCCAT 13

Db 6 CAGCGTGCCTCAT 18

RESULT 15

AR052624

LOCUS AR052624 18 bp DNA

DEFINITION Sequence 24 from patent US 5831066.

ACCESSION AR052624

VERSION AR052624.1 GI:5975988

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 18)

AUTHORS Reed,J.C.

TITLE Regulation of bcl-2 gene expression

JOURNAL Patent: US 5831066-A 24 03-NOV-1998;

FEATURES Location/Qualifiers

source 1..18

BASE COUNT 2 a 8 c 4 g 4 t

ORIGIN

Query Match 72.2%; Score 13; DB 5; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CAGCGTGCCTCAT 13
Db 6 CAGCGTGCCTCAT 18

Search completed: June 18, 2000, 20:47:01
Job time: 7121 sec

THIS PAGE BLANK (USPTO)
